

AMCoR

Asahikawa Medical University Repository <http://amcor.asahikawa-med.ac.jp/>

Parasitology (2013.Nov.) 140卷13号:1551~1565.

Nothing is perfect! Trouble-shooting in immunological and molecular studies of cestode infections.

Ito A

1 Ito A. Parasitology 2013; 140: 1551-1565

2

3

4

5 Review Article

6

7 **Nothing is perfect! Trouble-shooting in immunological and molecular studies on**
8 **cestode infections***

9

10

11 AKIRA ITO

12

13 *Department of Parasitology, Asahikawa Medical University, Asahikawa 078-8510,*

14 *Japan*

15

16 Corresponding author: Tel: +81 166 68 2686. Fax: +81 166 68 2429.

17 E-mail: akiraito@asahikawa-med.ac.jp

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33 SUMMARY

34 This unique review focuses on ways to approach and overcome some of the more
35 common issues encountered while studying cestode zoonoses. The information
36 presented here is based on the author's own experiences with immunological and
37 molecular approaches for the detection of these parasites. There are many incongruities
38 between immunological and molecular studies due to biased work. Nothing is perfect.
39 Indirect approaches using either immunological, or even molecular tools, are limited
40 without confirmation from direct evidence of infection. The dilemma of whether
41 developing countries should develop their own diagnostic tests or rely on commercially
42 available kits is also discussed.

43

44 Key word: taeniasis, cysticercosis, echinococcosis, diagnosis

45

46

47 INTRODUCTION

48 Zoonotic cestodiasis, including echinococcosis caused by several species of the genus
49 *Echinococcus*, cysticercosis caused by *Taenia solium*, and taeniasis caused by *T. solium*
50 and *Taenia saginata* are globally distributed. However, these conditions are considered
51 neglected due to the lack of tools for their detection and because they are given a low
52 priority in most countries (Ito *et al.* 2003a; Budke *et al.* 2006, 2009; Craig *et al.* 2007).
53 *Echinococcus* spp. requires herbivorous or omnivorous mammals as intermediate hosts
54 and carnivorous mammals as definitive hosts. By contrast, *T. solium* and *T. saginata*
55 require omnivorous or herbivorous mammals, mainly swine and cattle, respectively, as
56 intermediate hosts, and humans as definitive hosts (human taeniasis). Recently, a third
57 human taeniasis, caused by *Taenia asiatica*, was reported from Asia (Fan, 1988; Fan *et al.*
58 1990; Eom and Rim, 1993; Simanjuntak *et al.* 1997; Ito *et al.* 2003b; Eom, 2006;
59 Flisser *et al.* 2011). While *T. solium* cysticercosis can affect humans, other *Taenia* spp.,
60 such as *T. saginata* and *T. asiatica*, cause cysticercosis solely in livestock (Ito, 1992 vs
61 Ito *et al.* 2003b). Furthermore, cysticercosis in domestic animals are caused by
62 numerous other non-human *Taenia* spp. such as *T. hydatigena* (Euzéby, 1974).
63 Complicated and various life cycles and differences in pathogenicity in humans and
64 domestic animals also lead to these conditions being considered neglected (Budke *et al.*

65 2009). How to best evaluate human cysticercosis is still a complicated question and
66 more data are required to better assess risk factors associated with disease transmission.

67 In order to move towards improved treatment and control or eradication of cestode
68 zoonoses, we need to establish highly reliable indirect tools for detection of parasite
69 carriers. Since *Echinococcus* spp. requires mainly wild animals for the completion of its
70 life cycle, with the exception of *Echinococcus granulosus* (= *E. granulosus* sensu stricto,
71 Nakao *et al.* 2013a) which predominately has a domestic dog-livestock cycle,
72 establishing control interventions can be quite difficult. Due to the severity of disease
73 caused by some species of *Echinococcus*, such as *E. multilocularis*, which causes
74 alveolar echinococcosis (AE) and can resemble hepatic cancer, some endemic countries,
75 such as China, have started to give echinococcosis a higher priority.

76 By contrast, cysticercosis, due to *T. solium*, is commonly neglected because
77 asymptomatic taeniasis carriers are not officially detected and do not receive treatment.
78 In addition, cysticercosis is mainly endemic in poor villages where people eat pork
79 without meat inspection, with these populations having little political will (Ito *et al.*
80 2003c). It should be possible to eradicate human cysticercosis since transmission is
81 based on hygiene and food preparation practices (Schantz *et al.* 1993). Side effects may
82 occur when cases of human cysticercosis are treated with praziquantel (PZQ), however,
83 the severity and extent of these side effects is still largely unknown due to lack of data
84 (Pawlowski, 2006; Takayanagui *et al.* 2011; Jung-Cook, 2012; Baird *et al.* 2013; Ito *et*
85 *al.* 2013).

86 In this review article, I will summarize the importance of the application of modern
87 diagnostic tools for detection of humans and animals infected with these zoonotic
88 cestodes. I will also discuss how to evaluate the tools themselves, and address the
89 importance of real-time detection of taeniasis carriers. My purpose in writing this
90 unique review is to stress the importance in doing less biased work through some
91 cautionary tales from my own work (Ito, 1992), remembering that nothing is ever
92 perfect.

93

94 INDIRECT VERSUS DIRECT EVIDENCE OF INFECTION

95 Diagnostic imaging, antibody responses, and clinical background are very important to
96 help clinicians come to a definitive diagnosis of cysticercosis or echinococcosis before

97 treatment. However, advanced imaging (for example, ultrasound, computed tomography,
98 and magnetic resonance imaging) for cysticercosis and echinococcoses are not always
99 readily available and clinicians require specialized training to adequately interpret
100 available images. Neurocysticercosis (NCC) cases are often asymptomatic in endemic
101 areas. However, cases of subcutaneous cysticercosis (SCC) often have visible or
102 palpable lesions, with reports of SCC common in Asia (Ito *et al.* 2003d; Kobayashi *et al.*
103 2013). The only truly pathognomonic advanced imaging feature for cysticercosis is
104 visualization of an invaginated scolex in a cyst wall (Ito *et al.* 2006; Nash and Garcia,
105 2011; Del Brutto, 2012). In AE cases, imaging may look similar to other
106 space-occupying diseases, including hepatic cancers and other hepatic conditions,
107 including fascioliasis or amoebiasis (Eckert *et al.* 2001; Bresson-Hadni *et al.* 2006,
108 2011; Yang *et al.* 2007; Brunetti *et al.* 2010; Li *et al.* 2010).

109 More than one decade ago, major newspapers, in Japan, reported a single AE case on
110 the main island of Honshu. These reports stated that this killer parasite had invaded the
111 main island from the endemic island of Hokkaido. However, this information was based
112 solely on serology using crude antigen, which was not evaluated for cross reactions with
113 more common parasites such as *Fasciola* spp. If the researchers had checked antibody
114 responses using a panel of other parasitic infections, they would have determined that
115 there was no real evidence to support a diagnosis of AE (Ito *et al.* 2002a, 2003c). At that
116 time, I personally believed that there was no chance that *E. multilocularis* would
117 become established on the main island of Honshu, even though there were several
118 confirmed reports of accidental infections in pigs (Kimura *et al.* 2010), horses (Kaji *et*
119 *al.* 1993; Goto *et al.* 2010; Ueno *et al.* 2012) and dogs (Yamamoto *et al.* 2006) imported
120 from the endemic island of Hokkaido. However, after a tsunami hit Japan and atomic
121 power stations' explosion in Fukushima emerged in March of 2011, I changed my mind.
122 I now urge caution due to the escape of numerous livestock during post-tsunami
123 flooding as well as food sources for livestock, on the main island, being provided from
124 Hokkaido. As shown in Konyaev *et al.* (2013), numerous Galagos (or bush babies) in
125 the Moscow Zoo died of AE in 2010 and 2011, due to contaminated food and mulch
126 being brought in from an endemic area. In cystic echinococcosis (CE) cases, diagnostic
127 imaging findings are highly variable during the different developmental stages of the
128 cysts (Eckert *et al.* 2001; Brunetti *et al.* 2010). Therefore, clinicians often require

129 additional information to confirm a diagnosis, including serology and a working
130 knowledge of the epidemiology and clinical manifestations associated with this
131 condition.

132

133 *General problems in serology*

134 There are many review articles reporting serological studies on cestode zoonoses
135 (Gottstein, 1992; Craig *et al.* 1996; Siles-Lukas and Gottstein, 2001; Ito 2002; Ito and
136 Craig, 2003; Ito *et al.* 2006, 2007; Schantz, 2006; Deckers and Dorny, 2010; Nash and
137 Garcia, 2011; Del Brutto, 2012; Bames *et al.* 2012). Serodiagnostic tools have been
138 greatly improved based on new advanced knowledge and technology in immunology.
139 For example, the technology originally used for the indirect haemagglutination (IHA)
140 test has now been applied to a nano-magnetic particle agglutination test (Handali *et al.*
141 2010). Newly available tools have another benefit in that they use recombinant antigens
142 or synthetic peptides which can increase test specificity. However, these new tools are
143 expensive and often under patent, which restricts their use in poor developing countries
144 where neglected tropical diseases (NTDs) such as echinococcosis and cysticercosis are
145 prevalent (Handali *et al.* 2010; Lee *et al.* 2011).

146 When we used IHA two to three decades ago, our ability to purify and apply
147 diagnostic antigens was still in the early stages. IHA or enzyme-linked immunosorbent
148 assays (ELISA) using hydatid cyst fluid (HCF) from *E. granulosus* s.s. still lack
149 specificity for the detection of CE, but may be “better or much better than nothing in
150 mass screening where CE is highly endemic” (Mamuti *et al.* 2002; Mohammadzadeh *et*
151 *al.* 2012). In contrast, HCF is of little use for screening or detection of AE cases (Yu *et*
152 *al.* 2008). There is a report that describes specific antibody responses in horses naturally
153 infected with *E. multilocularis* (Ueno *et al.* 2012). However, the quality of the Western
154 blot (WB) results from the one AE sample used as a positive control was poor compared
155 to the results by Tappe *et al.* (2008). The findings strongly suggest that the quality of the
156 commercially available WB membrane was also very poor or expired. It is my belief
157 that a positive result might have been obtained regardless of the infection status of the
158 horse. Nonetheless, these serum samples appear to be useful or informative for further
159 studies.

160 Nowadays, we have improved skills for preparing highly purified antigens using new

161 biotechnological tools for the production of recombinant and synthetic proteins. There
162 are those with the opinion that personnel in endemic areas should buy highly reliable
163 test kits for mass screening or identification of individual patients. However, in the past,
164 when such kits were widely available commercially, the quality of the kits often was
165 very bad with poor quality control. These unreliable diagnostic kits can still be found
166 for sale today. One solution is that people in endemic areas or countries use their own
167 skills and knowledge to set up reference centers for the detection of infected humans
168 and animals. Experts in developed countries can be called upon to lend their expertise to
169 help develop appropriate diagnostic strategies in developing countries. There are many
170 good diagnostic materials which are readily available to conduct serology in endemic
171 areas. Therefore, we need to consider simple but reasonably reliable tools which are
172 easily introduced into these areas (Sako *et al.* 2013).

173

174 *ELISA versus WB*

175 It is widely believed that ELISA is highly useful for serological screening, but WB is
176 only helpful for confirmative serology. However, is this really correct? It might be
177 correct only when we use crude antigens, including cyst fluid from *T. solium* or other
178 related species, such as *T. hydatigena* or *T. crassiceps*, or HCF or crude antigens from
179 *Echinococcus* spp. These cyst fluids are, nonetheless, much better than crude antigens
180 extracted from the whole intact parasite, due to lesser amounts of non-specific
181 components. When we used crude antigens for ELISA, it was impossible for us to
182 differentiate specific antigen-antibody responses. These specific responses are more
183 useful for diagnosis than non-specific responses or antigen-antibody responses, which
184 are read based on a change in color of the ELISA solution and do not correlate as well
185 with diagnosis. However, if we use the same antigens for WB, we can visualize the
186 specific antigen-antibody responses as unique band(s) among a myriad of other bands
187 not helpful in diagnosis. Therefore, when we use such crude antigens with both specific
188 and nonspecific components, it is essential to be able to recognize and confirm the
189 specific band(s) that are diagnostically meaningful. This might not, however, always be
190 straight forward since it is possible to misidentify multiple components with similar
191 molecular weights as a single band, through insufficient running time on sodium
192 dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). Furthermore, if one

193 dimensional SDS-PAGE for routine WB is not sufficient to differentiate two or more
194 components with the same or very similar molecular weights, two dimensional
195 SDS-PAGE must be employed.

196 When we used highly purified antigen(s) which showed specific responses, there was
197 virtually no difference between ELISA and WB (Ito *et al.* 1998a, 1999a, 2007; Sako *et*
198 *al.* 2000, 2002; Müller *et al.* 2007). Dot-ELISA on nitrocellulose membrane may be
199 sufficient for detection of specific antibody responses onto the purified antigen and this
200 should be the same for the development of rapid immunochromatography (ICT) tests
201 (Sako *et al.* 2011). Therefore, identification of specific components for diagnosis,
202 purification of these components, and production of these components as recombinant
203 proteins or synthetic peptides is suggested. A more important objective may be to keep
204 or establish serum banks of confirmed human patients or animals, since it is difficult to
205 keep a sufficient number of confirmed serum samples, especially representing different
206 stage of these diseases. The development and maintenance of these serum banks should
207 be facilitated by the World Health Organization (WHO) and/or the Food and Agriculture
208 Organization of the United Nations (FAO).

209

210 *Is Em18 perfect for detection of active AE?*

211 As shown by Sako *et al.* (2002), Em18, ezrin-radixin-moesin (ERM)-like protein (ELP),
212 encoded by the gene *elp* (Brehm *et al.* 1999), is a degradation product through cysteine
213 proteases. Four components of ELP (EMII/3 (Gottstein *et al.* 1988), EM10 (Frosch *et al.*
214 1991), EM4 (Hemmings and McManus, 1991) and Em18 (Ito *et al.* 1993a)) have been
215 reported by four different groups. Em18 corresponds to a region with very limited
216 homology between the host and parasite ERM factors, which indicates that serology
217 using Em18 as an antigen might lead to more specific responses when compared with
218 full-length ELP (Ito *et al.* 2007). This strongly suggests that degradation products may
219 be detected, not from the early stage, but rather from the later stage of AE. If this is true,
220 it might suggest that detection of antibody responses to recombinant Em18 (RecEm18)
221 is useful for AE cases with active and advanced lesions (Ito *et al.* 1995; Tappe *et al.*
222 2008, 2009, 2010). According to Li *et al.* (2010b), 67% of AE1 cases were positive to
223 RecEm18, whereas 80%, 90% and 97% of AE2, AE3 and AEf cases, respectively were
224 positive to RecEm18. Therefore, the question arises of, “How should we interpret these

225 findings for AE1””? Is it possible for us to look for other components for serodiagnosis
226 of the early stage of AE? *E. multilocularis* metacestode vesicle fluid (EmVF) producing
227 bands at 20-22 kDa (Müller *et al.* 2007) and *E. multilocularis* major vault protein
228 (MVP) (Goto *et al.* 2013) may be alternative candidate antigens for diagnosis of early
229 stage AE cases if they prove to be more sensitive and specific than RecEm18.

230 Recently, we were presented with an early stage AE case, with a hepatic lesion
231 measuring approximately 1 cm in diameter. The patient was sero-negative by both
232 confirmative WB using crude antigen carried out at the Hokkaido Institute of Public
233 Health and RecEm18-WB carried out at Asahikawa Medical University (AMU).
234 However, when tested using crude antigen-WB at AMU, I found one very strong band
235 with a high molecular weight. It completely differs from any diagnostic components of
236 a commercially available WB kit (Liance *et al.* 2000). Therefore, crude antigen-WB
237 might also be useful for the serological detection of early stage of AE (Hagiwara *et al.*
238 [in prep.](#)). However, further studies are necessary. The use of highly purified antigen can
239 detect most, but not 100% of true cases, with very few false positives. However, when
240 we use crude antigen, we may detect more than 100% of cases with substantial numbers
241 of false positives ([Fig. 1](#)). Approximately one decade ago, serology applied in Hokkaido,
242 Japan using crude antigen-ELISA, showed that approximately 99% of cases positive by
243 crude antigen-ELISA were false positives. Unfortunately, this serological test
244 sometimes also failed in the detection of true AE cases which were easily confirmed by
245 RecEm18-WB (Ito *et al.* 2003b, c). Using crude antigens, we estimate that we obtain a
246 very large number of false positives and, possibly more importantly, false negatives.
247 However, it is not sure if false negatives are quite a few or not (Ito *et al.* 2002a, 2003c;
248 Aoki *et al.* 2006). In contrast, Em18-serology has proven to be much better for the
249 detection of AE cases, with almost no false positive cases in Japan (Ito *et al.* 1993a,
250 2003c, Aoki *et al.* 2006), China (Ito *et al.* 1993b), USA (Ito *et al.* 1995), Poland (Ito *et*
251 *al.* 1998a), France (Bart *et al.* 2006) and Germany (Tappe *et al.* 2008, 2009, 2010).
252 There are a few cases of early stage AE that have shown no antibody response to Em18
253 (Hagiwara *et al.* [in prep.](#)). However, I expect these cases will become positive over time.
254 There is no way to determine the number of false negative AE cases other than to utilize
255 different antigenic components or tools on stocked serum samples. Therefore, we must
256 decide on what is our true objective: Detection of 96-97% of AE cases with no false

257 positives or detection of 98% of AE cases with high numbers of false positives. An
258 alternative idea is to utilize fine needle aspiration for histopathological and molecular
259 confirmation of all stages of AE, since the risk of anaphylaxis is believed to be low for
260 AE cases (Kern *et al.* 1995; Kawakami *et al.* 2013).

261 There have been few reports stating that RecEm18 does not detect 100% of active AE
262 cases, but that other commercially available WB kit (Liance *et al.* 2000) could detect
263 100% of active AE cases (Furuya *et al.* 2004; Yamano *et al.* 2005). However, these
264 reports did not include other infectious disease samples for evaluation of the test's
265 specificity (Fig. 1). Furthermore, the authors did not use RecEm18, but instead used
266 crude antigens for identification of Em18-WB. It is necessary to run the SDS-PAGE for
267 a sufficient amount of time to have adequate separation of the various components (Ito
268 *et al.* 1993, 1995, 1997, 2002a, b; Liance *et al.* 2000; Tappe *et al.* 2008) and use some
269 specific markers such as monoclonal or polyclonal antibodies to Em16 or Em18 or any
270 other diagnostic components (Ito *et al.* 1993, 1995, 1998a; Jiang *et al.* 2001).

271 In South America, three *Echinococcus* spp., *E. granulosus* sensu stricto, *E.*
272 *canadensis* and *E. vogeli* are distributed. As the genes of Em18 and AgB are shared
273 among *Echinococcus* spp. (Nirmalan and Craig, 1997; Nakao *et al.* 2009) and the
274 expression of these genes are expected to be variable among the different pathological
275 feature of echinococcoses (Wen and Craig, 1994), we may expect that antibody
276 responses in *E. vogeli* infections (polycystic echinococcosis, PE) may be somewhere
277 between that of AE and CE (Knapp *et al.* 2009; Ito *et al.* 2011a).

278

279 *How rapidly do antibody responses to RecEm18 decline after curative surgery?*

280 Most recent serological follow-up studies of cured post-surgical hepatic AE cases in
281 Japan showed unexpected antibody responses (Fig. 2). For example, we were asked to
282 follow-up one AE cases for 6 months after surgery. After 6 months, antibody responses
283 to RecEm18 were already negative (data not shown). RecEm18 has been known to be a
284 good marker to follow-up the progression of AE especially in resected AE cases (Xiao
285 *et al.* 2003; Bart *et al.* 2007; Ishikawa *et al.* 2009; Tappe *et al.* 2009, 2010;
286 Bresson-Hadni *et al.* 2011). However, just recently it was shown that antibody
287 responses start to decline within only a few days post-surgery (Fig. 2-a, -c) (Akabane *et*
288 *al.* 2012). We have had several AE cases show similar drastic declines in antibody

289 responses within one week of curative surgery, with all becoming negative within 6
290 months (Fig. 2-b, -d) (Akabane *et al.* [in prep.](#)). This rapid decline in antibody response
291 may be true not only in AE cases, but also for other helminthic diseases or other
292 conditions requiring hepatic surgery. If this is confirmed, there might be some unknown
293 mechanism for inactivation of antibody responses after hepatectomy. Otherwise, we will
294 need to re-evaluate the immune memory itself using purified antigen(s). At present, AE
295 is the only parasitic disease where surgical resection of the entire lesion is
296 recommended as the first therapeutic choice. Very active homeostatic responses in
297 patients after surgery, anergy, or some unknown mechanism to induce a rapid drop in
298 antibody titers after surgery may exist and need to be evaluated further.

299

300 *Comparative studies using different tools including commercially available kits*

301 There are many reports that compare the specificity and sensitivity of diagnostic tools.
302 Studies where the test developers apply the various diagnostic tools are optimal in order
303 to reduce bias (Ito *et al.* [2002a](#)), unless the test(s) being evaluated are commercially
304 available (Ito *et al.* [1998b](#); Tappe *et al.* [2008](#); Carod *et al.* [2012](#)). Comparative studies
305 for serological tools that are not commercialized should be carried out by the two or
306 more groups that have been involved in the establishment of the tools (Dorny *et al.*
307 [2004](#)). Usually, such joint work should be carried out under blind or double blind
308 conditions (Ito *et al.* [1993](#), [1995](#), [2002b](#)). Otherwise, researchers who are interested in
309 using or evaluating another group's diagnostic tool should attempt to collaborate with
310 the test's developer (Li *et al.* [2003](#); Bart *et al.* [2007](#)). In all cases when serology is used,
311 it is important to consider ancillary findings (for example, diagnostic imaging and
312 clinical manifestations) to support the diagnosis since no test is 100% reliable (Tappe *et*
313 *al.* [2008](#), [2009](#)).

314

315 *Detection of specific antibodies versus detection of circulating antigens*

316 Most serological approaches are based on detection of specific antibody responses.
317 However, an alternative is to detect circulating antigens. The former cannot differentiate
318 current and previous infections due to immunological memory after cure. However,
319 there are no detailed follow-up studies on how long antibody responses remain after
320 surgical resection in cysticercosis or echinococcosis cases when using purified antigens.

321 Usually, clinicians try to follow the disease's progression via imaging and antibody
322 responses 6 months to one year after treatment. As an example, we were asked to check
323 antibody responses just prior to and one year after the surgical treatment of one NCC
324 case with a solitary lesion. The patient was seropositive before surgery, but completely
325 seronegative one year later (Ito *et al.* 1999b). The original serology applied at the
326 hospital was not sensitive and, therefore, the patient was believed to have a malignant
327 brain tumor. The lesion was surgically resected and later confirmed to be NCC. A
328 seronegative result one year post-surgery was not able to provide information on how
329 long the antibody response remained (Deckers and Dorny, 2010). In order to determine
330 length of antibody response, follow-up studies are required for both surgically treated
331 and chemotherapeutically managed cases (Kobayashi *et al.* 2013).

332 In the past, clinicians in Asia used to perform surgery for lung paragonimiasis which,
333 in Japan, was often misdiagnosed as lung tuberculosis (TB). However, after serology for
334 paragonimiasis was established and the drug, Bithionol, was commercially produced,
335 clinicians preferred chemotherapeutic therapy to surgery. Currently, we have no serum
336 samples from surgically treated paragonimiasis cases. If it is possible to acquire samples
337 from such cases and perform weekly or monthly post-surgical follow-up, we should be
338 able to determine if there is also a rapid decline in antibody titers with this parasitic
339 disease. Another interesting research topic could be how rapidly antibody responses in
340 NCC cases with surgery become negative post-surgery (Deckers and Dorny, 2010).

341 Serology to detect circulating antigens is expected to show evidence of an ongoing
342 infection. However, the specificity of these tests is still not entirely known. Almost all
343 antigen tests have been designed to detect certain components of metacestodes of *T.*
344 *saginata*, but not of *T. solium*. This means that the current antigen-based tools for *T.*
345 *solium* cysticercosis are based on cross reactions. The question is, "Why has no one
346 tried to produce specific antibodies to specific components of the metacestodes of *T.*
347 *solium*?" "*T. saginata*" based tests might be useful for detection of human cysticercosis,
348 since *T. solium* is essentially the only species which can infect humans other than very
349 rare cysticercosis cases caused by non-human *Taenia* spp. common in wild animals
350 (Euzéby, 1974). However, if this tool is used for the detection of pigs infected with *T.*
351 *solium*, there is no doubt that positive results would occur not only for pigs infected
352 with *T. solium*, but also for pigs infected with other taeniid cestodes, including *T.*

353 *hydatigena*. A joint project to evaluate antibody-ELISA and antigen-ELISA under blind
354 testing resulted in reasonably reliable results for the antibody-ELISA, with all pigs
355 harboring 16 or more cysticerci at necropsy 30 days after egg inoculation confirmed
356 antibody positive (Sato *et al.* 2003). In contrast, the sera from one uninfected pig
357 became antigen-ELISA positive based on the utilized cut-off.

358

359 *Which is better to use experimentally infected or naturally infected animal sera?*

360 Experimental infections to establish specific serodiagnosis are widely used. The
361 candidate diagnostic antigens are then applied for the detection of specific antibody
362 responses in patients or animals infected with the parasite species of interest. As *T.*
363 *solium* endemic areas tend to be located in poor regions of developing countries, people
364 and animals are often infected with multiple pathogens, including several other
365 helminthes. Therefore, serum samples from endemic areas are very useful for the
366 establishment of better diagnostic tests with higher specificity (Ito *et al.* 1999a). It is, for
367 this reason, that we often discuss how to establish negative controls. Ideally, negative
368 controls from endemic areas are better than negative controls from non-endemic
369 countries. However, if the antigens applied are specific enough, there may be no
370 difference between negative controls from endemic and non-endemic areas (Nkouawa *et*
371 *al.* 2011; Mohammadzadeh *et al.* 2012).

372 Pigs in developing countries are commonly infected with *T. hydatigena* and infection
373 with this parasite appears to be more common than infection with *T. solium* in Asia
374 (China, Thailand and Indonesia). There is a report that *T. hydatigena* is not common in
375 Africa (Dorny *et al.* 2004). However, no one knows if it is always and everywhere true.
376 Although we had no data on *T. hydatigena* from pigs that were confirmed to be
377 co-infected with *T. solium*, we applied our serological test, developed to detect human
378 cysticercosis, and found pigs naturally infected and confirmed positive for *T. solium*
379 infection in Indonesia (Papua), China, and Mexico (Ito *et al.* 1999a). Such results from
380 pigs confirmed to have been naturally infected with *T. solium* were ideal. Therefore, we
381 should use serum samples from pigs grown in endemic areas for evaluation of serology.

382 There has been a push to use an WB kit using glycoproteins (GP-WB) established for
383 detection of human cysticercosis (Tsang *et al.* 1989) for swine cysticercosis (Garcia *et*
384 *al.* 2003; DeGiorgio *et al.* 2005; Mwape *et al.* 2013). However, the GP-WB may only

385 be specific in humans who are exclusively infected with *T. solium*. This means that there
386 is no real control for evaluation of these GPs in animals which can be infected with
387 other taeniid cestodes. There are several reports discussing “transient antibodies”
388 detected by the GP-WB in swine cysticercosis (Garcia *et al.* 2003; DeGiorgio *et al.*
389 2005; Mwape *et al.* 2013). Therefore, it is suspected that some of the GPs are shared
390 with other non-human *Taenia* species (Lightowlers, 2013).

391

392 *Evaluation of serological results*

393 Use of advanced active cases of echinococcosis or cysticercosis to evaluate
394 serodiagnostic tools should increase test sensitivity. Therefore, serum samples with
395 good clinical background information are essential in the evaluation of serological
396 studies. In general, advanced cases are much easier to detect by any tool. If we use
397 purified antigens, the specificity becomes very high, but simultaneously the sensitivity
398 tends to be lower. In contrast, if we want a test that is 100% sensitive, we usually
399 sacrifice specificity. For a disease such as AE, it is essential to use a panel of serum
400 samples from other diseases such as hepatic cancers, cystic echinococcosis,
401 cysticercosis, fascioliasis, toxocariasis, amoebiasis, etc. The most important prerequisite
402 for such panels is that the panel sera have been confirmed antibody positive to the
403 homologous parasite or pathogen’s antigen. However, even with such careful analysis,
404 we may find shared epitopes among cestode or platyhelminthes, especially in terms of
405 hydrophobic ligand binding proteins including Antigen B family (Ioppo *et al.* 1996;
406 Ito, 2002; Mamuti *et al.* 2007; Jiang L *et al.* 2012; Mohammadzadeh *et al.* 2012;
407 Santivañez *et al.* 2012; Obal *et al.* 2012).

408

409 *Serology for detection of taeniasis*

410 There are serological tools available for the detection of taeniasis carriers due to *T.*
411 *solium*. However, to my knowledge, there is no scientifically sound work on how
412 species specific these tests are. Some group used no or few samples from *T. saginata* or
413 *T. asiatica*, but stressed that their newly developed serological test was 100% specific
414 for *T. solium*. If sera from people infected with other *Taenia* species were seronegative
415 to the homologous antigens, it resulted in a negative test. It is, therefore, difficult to
416 evaluate such work without blinded tests with greater numbers of samples. Nonetheless,

417 even if the test cannot differentiate species, it may still be useful for the detection of
418 taeniasis carriers. It should also be noted that such a serological tool for the detection of
419 taeniasis carriers cannot differentiate ongoing infection from past infection due to
420 immunological memory. Therefore, confirmation is needed on how long the antibody
421 responses remain after treatment. This problem pushes us to develop better tools for
422 molecular identification. Better parasite identification is also needed to assess
423 anthelmintic drug therapy. Salim *et al.* (2009) used commercially available serological
424 tools in Papua, Indonesia to perform serological screening of the local population. The
425 study reported the proportion of people who were taeniasis carriers or cysticercosis
426 patients. However, there was no direct evidence to confirm which *Taenia* species were
427 causing infection. We require better direct evidence of these parasites in people (Wandra
428 *et al.* 2000) pigs (Subahar *et al.* 2001; Margono *et al.* 2003) and even dogs (Ito *et al.*
429 2002c) in Papua (Wandra *et al.* 2013). Nonetheless, there are still better data on human
430 cases of echinococcoses, cysticercosis, and taeniasis compared with data on infections
431 in animals.

432

433 *Problems with animal surveys*

434 Detection of animals parenterally infected with metacestodes of *Echinococcus* spp. or
435 *Taenia* spp. is difficult due to the cost of performing diagnostic tests. There are no
436 practical tools for the detection of animals infected with *E. granulosus* sensu lato. The
437 same is true for other *Echinococcus* spp. infections in South America (Knapp *et al.*
438 2009; Santose *et al.* 2012). If echinococcoses were a more lethal in livestock and other
439 high value animals, the animal sector would be more likely to set up sustainable
440 screening for infections in animals.

441 In contrast, cattle infected with metacestodes of *T. saginata* are very rare in
442 developed countries; with most cases the result of infected employees from developing
443 countries contaminating farming areas by defecating in fields containing livestock
444 (Dorny and Praet, 2007; McFadden *et al.* 2011; Yanagida *et al.* 2012; Yamasaki, 2013).
445 If we introduce stool examination for all employees working in farming areas, it might
446 be cheaper than introducing a new serological tool to detect infected cattle.

447

448 *Copro-ELISA for detection of adult tapeworm carriers*

449 Copro-ELISA has been useful for detection of adult worms in definitive hosts, including
450 humans with taeniasis or dogs and/or foxes infected with *Echinococcus* spp. (Allan *et*
451 *al.* 1990, 1996; Deplazes *et al.* 1994, 1999; Allan and Craig, 2006). There are several
452 groups which have been working on copro-ELISA tests. Most of them use polyclonal
453 antibodies to capture antigens in fecal samples. These tests performed well in laboratory
454 based studies, especially when known positives were compared with uninfected
455 negative controls. However, in field studies in endemic areas where other parasitic
456 infections were common, it became much more difficult to interpret test results (Raoul
457 *et al.* 2001). Copro-ELISA appeared to work better in earlier projects, indicating that
458 expired capturing antibodies prepared approximately 2 decades ago may be affecting
459 the test's outcome in more recent studies (Hartnack *et al.* 2013). In order to address the
460 problem with specificity, some groups have applied monoclonal antibodies to capture
461 the antigens (Nonaka *et al.* 1996; Morel *et al.* 2013). However, most of the antigenic
462 components in faeces were not proteins, but rather glycoproteins or lipoproteins, which
463 may result in non-specific responses. Even if such antibodies for capturing proteins,
464 sugars, or lipids were specific, there might be blockers or inhibitors in the fecal samples.
465 Therefore, it is not possible to know if these copro-ELISA tests are useful without direct
466 evidence of infection (for example, eggs or tapeworms) from copro-ELISA positive
467 humans or animals.

468

469 *Molecular identification of cestode species*

470 Molecular identification is almost 100% reliable when applied to parasites collected
471 from human patients or infected animals. However, contamination of tools with other
472 DNA may cause erroneous results. Therefore, repeated analyses of the same samples at
473 different laboratories may be important for evaluation of the results (Hüttner *et al.* 2008;
474 Knapp *et al.* 2009; Snabel *et al.* 2009). There is also the risk of contamination,
475 especially by beginners, which may even result in unreliable sequences being inputted
476 into GenBank.

477 Eggs, metacestodes and adult tapeworms are all targets for molecular identification.
478 Even though eggs of taeniid species cannot be differentiated morphologically, they can
479 be differentiated using molecular tools. Based on the obtained molecular data, we
480 should treat tapeworm carriers and collect adult worms. Morphology and molecular

481 information from adult worms should also be compared with molecular data obtained
482 from parasite eggs.

483 The merit of using coproDNA detection is that DNA of immature worms can be
484 amplified. Therefore, coproDNA detection may be more sensitive and reliable for all
485 stages of the worm's development in the host intestine. Polymerase chain reaction
486 (PCR) has widely been applied for coproDNA detection (Yamasaki *et al.* 2004).
487 However, inhibitors in the faeces may interfere with the test. Recent approaches using
488 loop-mediated isothermal amplification (LAMP) for copro-tests, coproLAMP, are more
489 reliable, with almost no influence from such inhibitors (Nkouawa *et al.* 2009, 2010,
490 2012).

491 Recent molecular studies of *Echinococcus* spp. have revealed that *E. granulosus*
492 sensu lato consists of 5 independent species: *E. granulosus*, *E. equinus*, *E. ortleppi*, *E.*
493 *canadensis* and *E. felidis* (Nakao *et al.* 2007, 2010, 2013a; Hüttner *et al.* 2008; Knapp *et*
494 *al.* 2009). Furthermore, the hermaphroditic nature of cestodes allows them to reproduce
495 without sexual reproduction. However, infection with multiple worms may result in
496 outcrossing. Such data may be obtained for *Echinococcus* spp. when we compare
497 mitochondrial (haploid) and nuclear (diploid) DNA from *Echinococcus* worms in a
498 single definitive host co-infected with different species of *Echinococcus* or different
499 genotypes of worms. There are also reports stressing that *E. granulosus* and *E.*
500 *multilocularis* parasitize different parts of the dog intestine, while other reports state that
501 the two species parasitize the same regions of the intestine (Thompson and Eckert,
502 1983; Kumalatilake *et al.* 1986; Lymbery *et al.* 1989). However, it is not known if these
503 reports can be generalized to all dogs and other canids. There might be hybrids of, or at
504 least introgression between, *E. granulosus* s.s. and *E. canadensis* (Barts *et al.* 2006) or
505 other species of *E. granulosus* s.l. where these species are co-endemic. Therefore, it is
506 possible that morphologically indistinguishable hybrid species may be found in the
507 small intestine, but additional data are needed.

508 Evidence of outcrossing has been suggested from *E. multilocularis*, in Hokkaido,
509 Japan, using microsatellite DNA (Nakao *et al.* 2003) as well as from *T. saginata* and *T.*
510 *asiatica*. In these cases, although the mtDNA indicated *T. asiatica*, nuclear DNA
511 indicated *T. saginata*, or highly variable heterozygotes of both species, and *vice versa*
512 (Okamoto *et al.* 2010; Yamane *et al.* 2012, 2013). Experimental infection with eggs of *T.*

513 *asiatica* by Fan *et al.* (1990) resulted in *T. asiatica* metacestodes developing in the
514 viscera of pigs, but also produced metacestodes in cattle and other domestic animals.
515 This led to additional studies on this new Asian *Taenia* species (Simanjuntak *et al.* 1997;
516 Wandra *et al.* 2013; Yamane *et al.* 2013), which leads to the question of “Are there any
517 other human *Taenia* species”? In Ethiopia, cysticerci from a new *Taenia* species have
518 recently been confirmed from cattle (Hailemariam *et al.* 2013). We, therefore, are facing
519 a more complicated world in the area of taeniid cestode taxonomy (Nakao *et al.* 2013b).
520 Coevolution of cestodes and host animals are other emerging topics.

521

522 *Pathogenicity of Echinococcus spp. to humans*

523 Recent molecular studies have revealed that *E. granulosus* s.s. and *E. felidis* (Hüttner *et*
524 *al.* 2008), and *E. multilocularis* and *E. shiquicus* (Xiao *et al.* 2005) are sister species,
525 respectively, with the former species, of both pairs, known to be highly pathogenic to
526 humans (Nakao *et al.* 2010; Knapp *et al.* 2011). Therefore, it is hypothesized that these
527 two newer species, *E. felidis* in Africa and *E. shiquicus* in Tibet, China can also infect
528 humans. However, we should not jump to conclusions until we have concrete evidence
529 of human infections. All CE samples due to *E. granulosus* s.s. in Africa, especially
530 where *E. felidis* has been confirmed, should be re-evaluated for the possibility of *E.*
531 *felidis*.

532

533 *The importance of the real time detection of taeniasis carriers and cysticercotic pigs*

534 We have been working on taeniasis and cysticercosis in several Asian countries. Since
535 2004, the Ministry of Education, Japan, has sponsored numerous seminars to help
536 transfer technology to scientists in Asia and Africa. Parasite materials and human
537 samples from endemic areas have been analyzed at AMU after obtaining ethical
538 approval. Molecular identification of *Taenia* species using eggs, metacestodes, adult
539 worms, fecal samples, and serology have been carried out by junior colleagues from
540 endemic countries. Unfortunately, it has been very difficult to locate identified taeniasis
541 carriers for treatment because many had moved in the time between sampling and
542 diagnosis. Therefore, we have decided to establish a real-time detection system in order
543 to identify and treat carriers during a single visit as well as immediately identify pigs
544 that show evidence of being infected (Ito *et al.* 2011). This method was first employed

545 in Bali in 2011 (Swastika *et al.* 2012). To use the ELISA for pigs, in the field, an ELISA
546 reader is not required since a color change indicates a positive result. Thus far, all
547 ELISA positive pigs examined in Bali, Indonesia, were confirmed to have *T. solium*
548 cysticerci, with or without *T. hydatigena*. When we used an ELISA-reader to check the
549 cut-off border line samples in the laboratory, some of these samples were weak positives
550 and some were confirmed to harbour *T. hydatigena* on necropsy (Dharmawan *et al.* in
551 prep.). Therefore, we believe that the use of a color change ELISA may be sufficient or
552 better for screening and identifying pigs infected with *T. solium* under field conditions
553 (Fig. 3). However, more work is necessary. A LAMP test that can be used in the field
554 and does not require electricity has also been developed (Nkouawa *et al.* 2012).
555 Real-time identification of taeniasis carriers and pigs infected with *T. solium*, in
556 endemic areas, is essential to demonstrate risk factors for human cysticercosis.

557

558 *Dilemma for intervention of cysticercosis or echinococcoses in developing countries:*
559 *What is the contribution of commercially available kits?*

560 A serious problem with the application of modern diagnostic tools is that we often use
561 such tools but do not work to obtain direct evidence of the infection itself. This
562 oversight should be avoided. As mentioned above, serology for the detection of
563 cysticercosis in endemic areas of Asia is not difficult even when applying simple
564 purification tools (Sako *et al.* 2013). Therefore, we are strongly recommending keeping
565 metacestodes from pigs (Fig. 3) and trying to purify the diagnostic antigens using a
566 simple and inexpensive method (Sako *et al.* 2013). Commercial kits may be more useful
567 in developed countries, especially in the USA, since the USA has many cysticercosis
568 cases due to refugees or immigrants from endemic areas. In addition, US citizens may
569 bring back the parasite to USA, after visiting countries where *T. solium* infections are
570 endemic (Serpa *et al.* 2011; Sorvillo *et al.* 2011; Yanagida *et al.* 2010, 2012;
571 Jongwietiwes *et al.* 2011).

572 One serious disadvantage from the use of commercially available kits is the
573 possibility of discouraging researchers in endemic developing countries to establish
574 tools for their own use. Another serious issue is a lack of knowledge on how to evaluate
575 potentially erroneous data from the kits. There are many kits on the market, with many
576 of the tests appearing to lose reliability after being commercialized. Based on this view

577 point, in 2004 I started to encourage personnel in Asia and Africa to understand the
578 mechanism of antigen-antibody responses using their own samples and develop purified
579 antigens to establish their own ELISA or IB serological tests (Ito, 2007). However, at
580 the same time, I was encouraged to produce rapid serological kits for AE, CE and
581 cysticercosis by the Ministry of Education, Japan (ADAMU-AE, -CE and -CC: ICST
582 Co. Ltd., Saitama, Japan). Evaluation of commercially available kits is recommended
583 by the WHO, and numerous other organizations.

584 No test is 100% reliable, but we should challenge ourselves to get better results using
585 confirmed patients' sera. After this, we can apply the tools on suspected cases or utilize
586 them in epidemiological surveys for confirmation of the infection itself.

587

588 CHEMOTHERAPY OF TAENIASIS IN REMOTE AND RURAL AREAS IN ASIA

589 In Southeast Asian countries, eggs of *Taenia* spp. may be found through stool
590 examination for soil transmitted helminthes (STH). However, the number of samples
591 with *Taenia* eggs will be very small compared with eggs of the major STHs. Therefore,
592 there is usually no further analysis for the identification of *Taenia* species, since
593 identification of *Taenia* species is time consuming and morphological identification is
594 dependent on the adult worm being expelled. Therefore, we need molecular tools for
595 identification of the species. As a result of the inability in adequate identification of
596 *Taenia* species, these cestodes have been further neglected in relation to the other STHs
597 and/or fish-borne trematodiasis (FBTs). However, if the eggs of *Taenia* spp. are
598 identified to be *T. solium*, it means that there is a risk cysticercosis to both the carrier
599 and his or her family members and others in the community (Montresor and Palmer,
600 2006). The WHO has recommended mass treatment with praziquantel (PZQ) even
601 though there can be safety issues with mass treatment. There are records of individuals
602 dying within days of treatment as part of mass treatment campaigns against
603 schistosomiasis and/or FBTs (Ito *et al.* 2013), but there have been no analyses of the
604 cause of these sudden deaths. If the areas endemic for schistosomiasis and/or other
605 trematodiasis are also endemic for *T. solium*, these sudden deaths could be due to NCC
606 cases who succumb due to a side effect of PZQ treatment since, in these cases, PZQ can
607 results in acute seizures or convulsions when given without a steroid (Pawlowski 2006;
608 Wandra *et al.* 2011). Therefore, we need to reconsider the danger of PZQ for treatment

609 of NCC, especially during mass treatment campaigns where there could be numerous
610 asymptomatic cases. In Asia, we need to establish a better strategy for the detection of
611 taeniasis and cysticercosis using highly reliable immunological and molecular tools.

612

613 CONCLUSIONS

614 Taeniasis are neglected due to the small number of cases detected via screening for
615 STHs and the fact that *Taenia* eggs in human faeces are impossible to identify to the
616 species level. The highly pathogenic *T. solium* should be differentiated from the two less
617 pathogenic species (*T. saginata* and *T. asiatica*) by morphology of the tapeworm's
618 scolex or by molecular tools, including copro tests. Serology and imaging are still
619 necessary for evaluation of human cases of echinococcosis and cysticercosis. A more
620 complicated situation remains in terms of identification of animal infections. There are
621 many acute and chronic infectious diseases. Due to the small population of known
622 patients or carriers of cestode zoonoses, these conditions will continue to be neglected
623 until an outbreak occurs in a developed country. As the risk of infection in people is
624 primarily from individuals living in remote areas of developing countries, we are faced
625 with numerous challenges for controlling these neglected cestode zoonoses. We have to
626 keep in mind that "Nothing is perfect without direct evidence of the infection". In this
627 article, I did not discuss vaccination trials due to a lack of individual experience.
628 However, there are numerous references that describe this topic in detail (Lightowers,
629 [2006](#), [2010a](#), [2010b](#), [2010c](#), [2013](#); Bethony *et al.* [2011](#); Gauci *et al.* [2013](#)).

630

631 ACKNOWLEDGEMENTS

632 I sincerely thank Christine Budke for her amendment of this article and valuable
633 comments and suggestions, and Hiromitsu Akabane who has treated AE cases at
634 Asahikawa Kosei Hospital. I highly appreciate the Ministry of Education, Japan for its
635 sustained support that has allowed me to establish a network with the goal of controlling
636 cestode zoonoses in Asia and in Africa from 1994 onwards. Over the last decade, my
637 research team has invited more than 100 researchers from Asia and the Pacific (Korea,
638 Taiwan, China, Mongolia, Kazakhstan, Philippines, Vietnam, Lao PDR, Thailand, Nepal,
639 India, Indonesia, Papua New Guinea, Australia, New Zealand), Africa (Tanzania,
640 Mozambique, Kenya, Sudan, Egypt, Senegal, Cameroon, Ethiopia), the Middle East

641 (Iran, Jordan), the Americas (USA, Mexico, Brazil, Ecuador, Peru, Argentina) and
642 Europe (UK, France, Germany, Poland, Switzerland, Italy, Slovenia, Finland, Russia) to
643 conduct joint collaborative work for the establishment and evaluation of serological and
644 molecular tools for diagnosis, as well as organize international workshops and
645 symposiums (Ito *et al.* 2003c, 2011, 2013; Ito, 2007). I have enjoyed international
646 projects with more than 250 collaborators from 45 countries.

647 I am grateful to all of those who worked on these topics and encouraged me, especially
648 Schantz, P. M., Craig, P. S., Mitchell, G. F., Rickard, M. D., Lightowlers, M. W.,
649 Pawlowski, Z. S., Lord Soulsby, Smyth, J. D., Urbani, C., Fan, P. C., Cross, J., Rausch,
650 L. R., and all my Japanese collaborators. *I dedicate this article to my wife, Hikari Ito
651 who continuously encouraged my international research collaboration for over 30 years
652 but passed away in Kyoto on 30 May 2012.

653

654

655 FINANCIAL SUPPORT

656 The studies by the author's research team were supported by Grant-in-Aid for scientific
657 research (1994-2015), Asia-Africa Scientific Platform Funds (2006-2008, 2009-2011),
658 Challenging Exploratory Research Fund (2010-2011) from the Japan Society for the
659 Promotion of Science, and Infection Matrix Fund (2007-2008), the Hokkaido
660 Translational Research Fund (2007-2011) and the Special Coordination Fund for
661 Promoting Science and Technology (2003-2005, 2010-2012) from the Ministry of
662 Education, Culture, Sports, Science & Technology in Japan (MEXT), and from the
663 Fogarty International Centre of the National Institutes of Health (Grants RO1
664 TW001565, RO1 TW001665)(2000-2008)(PI: Craig, P.S.). The content is solely the
665 author's responsibility and does not necessarily represent the official views of the
666 funders.

667

668 REFERENCES

669 **Akabane, H., Nakano, S., Inagaki, M., Yanagida, N., Shoumura, H., Kudo, T.,**
670 **Shonaka, T., Orimo, T., Oikawa, F., Aiyama, T., Shibaki, T., Sako, Y., Itoh, S.**
671 **and Ito, A.** (2012). Evaluation of a long term follows up by imaging and serology
672 on a hepatic alveolar echinococcosis at Asahikawa Kousei Hospital. *Hokkaido*

673 *Nouson Igaku* **44**, 38-44 (in Japanese).

674 **Allan, J.C., Avila, G., Garcia Noval, J., Flisser, A. and Craig, P.S.** (1990).
675 Immunodiagnosis of taeniasis by coproantigen detection. *Parasitology* **101**,
676 473-477.

677 **Allan, J.C. and Craig, P.S.** (2006). Coproantigens in taeniasis and
678 echinococcosis. *Parasitology International* **55**, S75-S80.

679 **Allan, J.C., Velasquez-Tohom, M., Torres-Alvarez, R., Yurrita, P. and**
680 **Garcia-Noval, J.** (1996). Field trial of the coproantigen-based diagnosis of
681 *Taenia solium* taeniasis by enzyme-linked immunosorbent assay. *American*
682 *Journal of Tropical Medicine and Hygiene* **54**, 352–356.

683 **Aoki, T., Kino, S., Yamazaki, H., Obara, M., Kasai, S., Yamasaki, H. and Ito,**
684 **A.** (2006). A case of liver cysts with Em18-WB was useful for differential
685 diagnosis. *Nihon Shokakibyō Gakkai Zasshi* **103**, 955-960 (in Japanese).

686 **Baird, R. A., Wiebe, S., Zunt, J. R., Halperin, J. J., Gronseth, G. and Roos, K.**
687 **L.** (2013). Evidence-based guideline: Treatment of parenchymal
688 neurocysticercosis: Report of the Guideline Development Subcommittee of the
689 American Academy of Neurology. *Neurology* **80**, 1424-1429.

690 **Bames, T. S., Deplazes, P., Gottstein, B., Jenkins, D. J., Mathis, A.,**
691 **Siles-Lucas, M., Torgerson, P. R., Ziadinov, I. and Heath, D. D.** (2012).
692 Challenges for diagnosis and control of cystic hydatid disease. *Acta Tropica* **123**,
693 1-7.

694 **Bart, J. M., Abdukader, M., Zhang, Y. L., Lin, R. Y., Wang, Y. H., Nakao, M.,**
695 **Ito, A., Craig, P. S., Piarroux, R., Vuitton, D. A. and Wen, H.** (2006).
696 Genotyping of human cystic echinococcosis in Xinjiang, PR China. *Parasitology*
697 **133**, 571-579.

698 **Bart, J. M., Piarroux, M., Sako, Y., Grenouillet, F., Bresson-Hadni, S.,**
699 **Piarroux, R. and Ito, A.** (2007). Comparison of several commercial kits and
700 Em18 serology for detection of human alveolar echinococcosis. *Diagnostic*
701 *Microbiology and Infectious Disease* **59**, 93-95.

702 **Brehm, K., Jensen, K., Frosch, P. and Frosch, M.** (1999). Characterization of
703 the genomic locus expressing the ERM-like protein of *Echinococcus*
704 *multilocularis*. *Molecular and Biochemical Parasitology* **100**, 147-152.

705 **Bethony, J. M., Cole, R. N., Guo, X., Kamhawi, S., Lightowers, M. W.,**
706 **Loukas, A., Petri, W., Reed, S., Valenzuela, J. G. and Hotez, P. J.** (2011).
707 Vaccines to combat the neglected tropical diseases. *Immunological Reviews* **239**,
708 237-270.

709 **Bresson-Hadni, S., Delabrousse, E., Blagosklonov, O., Bartholomot, B.,**
710 **Koch, S., Miguet, J. P., Mantion, G. A. and Vuitton, D. A.** (2006). Imaging
711 aspects and non-surgical interventional treatment in human alveolar
712 echinococcosis. *Parasitology International* **55**, S267-S272.

713 **Bresson-Hadni, S., Blagosklonov, O., Knapp, J., Grenouillet, F., Sako, Y.,**
714 **Delabrousse, E., Brientini, M. P., Richou, C., Minello, A., Antonino, A. T.,**
715 **Gillet, M., Ito, A., Mantion, G. A. and Vuitton, D. A.** (2011). Should possible
716 recurrence forbid liver transplantation in patients with end-stage alveolar
717 echinococcosis? A 20-yr follow up. *Liver Transplantation* **17**, 855-865.

718 **Brunetti, E., Kern, P., Vuitton, D. A. and Writing Panel for the WHO-IWGE.**
719 (2010). Expert consensus for the diagnosis and treatment of cystic and alveolar
720 echinococcosis in humans. *Acta Tropica* **114**, 1-16.

721 **Budke, C. M., Deplazes, P. and Torgerson, P. R.** (2006). Global socioeconomic
722 impact of cystic echinococcosis. *Emerging Infectious Diseases* **12**, 296-303.

723 **Budke, C. M., White, A. C. Jr. and Garcia, H. H.** (2009). Zoonotic larval
724 cestode infections: neglected, neglected tropical disease? *PLoS Neglected*
725 *Tropical Diseases* **3**, e319.

726 **Carod, J. F., Randrianarison, M., Razafinahefa, J., Ramahefarisoa, R. M.,**
727 **Rakotondrazaka, M., Debruyne, M., Dautigny, M., Cazal, P., Andriantseho,**
728 **M. L. and Charles, E. R.** (2012). Evaluation of the performance of 5
729 commercialized enzyme immunoassays for the detection of *Taenia solium*
730 antibodies and for the diagnosis of neurocysticercosis. *Diagnostic Microbiology*
731 *and Infectious Disease* **72**, 85-89.

732 **Craig, P. S., Rogan, M. T. and Allan, J. C.** (1996). Detection, screening and
733 community epidemiology of taeniid cestode zoonoses. *Advances in Parasitology*
734 **38**, 169-250.

735 **Craig, P. S., Budke, C. M., Schantz, P. M., Li, T., Qiu, J., Yang, Y., Zeyhle, E.,**
736 **Rogan, M. T. and Ito, A.** (2007). Human echinococcosis: a neglected disease?

737 *Tropical Medicine and Health* **35**, 283-292.

738 **Deckers, N. and Dorny, P.** (2010). Immunodiagnosis of *Taenia solium*
739 taeniosis/cysticercosis. *Trends in Parasitology* **26**, 137-144.

740 **Del Brutto, O. H.** (2012). Neurocysticercosis: a review. *The Scientific World*
741 *Journal* **2012**, 159821.

742 **Deplazes, P., Alther, P., Tanner, I., Thompson, R. C. and Eckert, J.** (1999).
743 *Echinococcus multilocularis* coproantigen detection by enzyme-linked
744 immunosorbent assay in fox, dog and cat population. *Journal of Parasitology* **85**,
745 115-121.

746 **Deplazes, P., Jimenez-Palacios, S., Gottstein, B., Skaggs, J. and Eckert, J.**
747 (1994). Detection of *Echinococcus* coproantigens in stray dogs of northern Spain.
748 *Applied Parasitology* **35**, 297-301.

749 **Dorny, P. and Praet, N.** (2007). *Taenia saginata* in Europe. *Veterinary*
750 *Parasitology* **149**, 22-24.

751 **Dorny, P., Phiri, I. K., Vercruyssen, J., Gabriel, S., Willingham, A. L. III.,**
752 **Brandt, J., Victor, B., Speybroeck, N. and Berkvens, D.** (2004). A Bayesian
753 approach for estimating values for prevalence and diagnostic test characteristics
754 of porcine cysticercosis. *International Journal for Parasitology* **34**, 569-576.

755 **Eckert, J., Gemmell, M. A., Meslin, F. X. and Pawlowski, Z. S.** (2001).
756 WHO/OIE Manual on Echinococcosis in Humans and Animals: a Public Health
757 Problem of Global Concern. 1-265. OIE, Paris.

758 **Eom, K. S.** (2006). What is Asian *Taenia*? *Parasitology International* **55**,
759 S137-S141.

760 **Eom, K. S. and Rim, H. J.** (1993). Morphologic descriptions of *Taenia asiatica*
761 sp.n. *Korean Journal of Parasitology* **31**, 1-6.

762 **Euzéby, J. A.** (1974). Zoonotic cestodes. In *Parasitic Zoonoses Clinical and*
763 *Experimental studies* (ed. Soulsby, E. J. L.), pp. 151-178, Academic Press, New
764 York.

765 **Fan, P. C.** (1988). Taiwan *Taenia* and taeniasis. *Parasitology Today* **4**, 86-88.

766 **Fan, P. C., Soh, C. T. and Kosin, E.** (1990). Pig as a favorable intermediate host
767 of a possible new species of *Taenia* in Asia. *Yonsei Reports of Tropical Medicine*
768 **21**, 39-58.

769 **Flisser, A., Craig, P. S. and Ito, A.** (2011). *Taenia solium*, *Taenia saginata* and
770 *Taenia asiatica*. In *Zoonoses* (eds. Palmer, S.R., Lord Soulsby, Torgerson, P.R.
771 and Brown, D.W.G.), 627-644. Oxford University Press, Oxford.

772 **Frosch, P. M., Frosch, M., Pfister, T., Schaad, V. and Bitter-Suemann, D.**
773 (1991). Cloning and characterization of an immunodominant major surface
774 antigen of *Echinococcus multilocularis*. *Molecular and Biochemical Parasitology*
775 **48**, 121-130.

776 **Furuya, K., Kawanaka, M., Yamano, K., Sato, N. and Honma, H.** (2004).
777 Laboratory evaluation of commercial immunoblot assay kit for serodiagnosis of
778 *Echinococcus* infections using sera from patients with alveolar hydatidosis in
779 Hokkaido. *Kansenshogaku Zasshi* **78**: 320-326 (in Japanese).

780 **Garcia, H. H., Gonzalez, A. E., Gilman, R. H., Palacios, L. G., Jimenez, I.,**
781 **Rodriguez, S., Verastegui, M., Wilkins, P., Tsang, V. C. W. and The**
782 **Cysticercosis Working Group in Peru.** (2001). Transient antibody response in
783 *Taenia solium* infection in field conditions—A major contributor to high
784 seroprevalence. *American Journal of Tropical Medicine and Hygiene* **65**, 31-32.

785 **Garcia, H. H., Gonzalez, A. E., Gavidia, C., Falcon, N., Bernal, T., Verastegui,**
786 **M., Rodriguez, S., Tsang, V. C., Gilman, R. H. and Cysticercosis Working**
787 **Group in Peru.** (2003). Seroincidence of porcine *T. solium* infection in the
788 Peruvian highlands. *Preventive Veterinary Medicine* **57**, 227-236.

789 **Gauci, C., Jayashi, C. and Lightowers, M. W.** (2013). Vaccine development
790 against the *Taenia solium* parasite: The role of recombinant protein expression
791 in *Escherichia coli*. *Bioengineered* **4**, in press.

792 **Goto, A., Kouguchi, H., Yamano, K. and Sawada, Y.** (2013). Molecular cloning
793 and characterization of major vault protein of *Echinococcus multilocularis*.
794 *Experimental Parasitology* **134**, 102-108.

795 **Goto, Y., Sato, K., Yahagi, K., Komatsu, O., Hoshina, H., Abiko, C.,**
796 **Yamasaki, H. and Kawanaka, M.** (2010). Frequent isolation of *Echinococcus*
797 *multilocularis* from the livers of racehorses slaughtered in Yamagata, Japan.
798 *Japanese Journal of Infectious Diseases* **63**, 449-451.

799 **Gottstein, B.** (1992). Molecular and immunological diagnosis of echinococcosis.
800 *Clinical Microbiology Reviews* **5**, 248-261.

801 **Gottstein, B., Muller, N. and Seebeck, T.** (1988). Production of a recombinant
802 antigen of *Echinococcus multilocularis* with high immunodiagnostic sensitivity
803 and specificity. *Molecular and Biochemical Parasitology* **31**, 117-125.

804 **Hailemariam, Z., Nakao, M., Menkir, S., Lavikainen, A., Iwaki, T., Yanagida,**
805 **T., Okamoto, M. and Ito, A.** (2013). Molecular identification of species of *Taenia*
806 causing bovine cysticercosis in Ethiopia. *Journal of Helminthology*, in press.

807 **Handali, S., Klarman, M., Gaspard, A. N., Dong, X. F., LaBorde, R., Noh, J.,**
808 **Lee, Y., Rodriguez, S., Gonzalez, A. E., Garcia, H. H., Gilman, R. H., Tsang,**
809 **V. C. W. and Wilkins, P.** (2010). Development and evaluation of a magnetic
810 immunochromatographic test to detect *Taenia solium* which causes taeniasis
811 and neurocysticercosis in humans. *Clinical and Vaccine Immunology* **17**,
812 631-637.

813 **Hartnack, S., Budke, C. M., Craig, P. S., Jiamin, Q., Boufana, B.,**
814 **Campos-Ponce, M. and Torgerson, P. R.** (2013). Latent-class methods to
815 evaluate diagnostics tests for *Echinococcus* infections in dogs. *PLoS Neglected*
816 *Tropical Diseases* **7**, e2068.

817 **Hemmings, L. and McManus, D. P.** (1991). The diagnostic value and molecular
818 characterization of an *Echinococcus multilocularis* antigen gene clone.
819 *Molecular and Biochemical Parasitology* **44**, 56-62.

820 **Hüttner, M., Nakao, M., Wassermann, T., Siefert, L., Boomker, J. D. F., Dinkel,**
821 **A., Sako, Y., Mackenstedt, U., Romig, T. and Ito, A.** (2008). Genetic
822 characterization and phylogenetic position of *Echinococcus felidis* Ortlepp, 1937
823 (Cestoda: Taeniidae) from the African lion. *International Journal for Parasitology*
824 **38**, 861-868.

825 **Iopposito, S., Notargiacomo, S., Profumo, E., Franchi, C., Ortona, E., Rigano,**
826 **R. and Siracusano, A.** (1996). Immunological responses to antigen B from
827 *Echinococcus granulosus* cyst fluid in hydatid patients. *Parasite Immunology* **18**,
828 571-578.

829 **Ishikawa, Y., Sako, Y., Itoh, S., Ohtake, T., Kohgo, Y., Matsuno, T., Ohsaki, Y.,**
830 **Miyokawa, N., Nakao, M., Nakaya, K. and Ito, A.** (2009). Serological
831 monitoring of progression of alveolar echinococcosis with multi-organ
832 involvement using recombinant Em18. *Journal of Clinical Microbiology* **47**,

833 3191-3196.

834 **Ito, A.** (1992). Cysticercosis in Asia-Pacific region. *Parasitology Today* **8**, 182.

835 **Ito, A.** (2002). Serologic and molecular diagnosis of zoonotic larval cestode
836 infections. *Parasitology International* **51**, 221-235.

837 **Ito A.** (2007). Welcome remark and introduction to symposium on cestode
838 zoonoses in Asia and the Pacific. *Southeast Asian Journal of Tropical Medicine*
839 *and Public Health* **38** (Suppl. 1), 115-118.

840 **Ito, A. and Craig, P. S.** (2003). Short Review: Immunodiagnostic and molecular
841 approaches for the detection of taeniid cestode infections: *Trends in*
842 *Parasitology* **19**, 377-381.

843 **Ito, A., Nakao, M. and Sako, Y.** (2007). Echinococcosis: serological detection of
844 patients and molecular identification of parasites. *Future Microbiology* **2**,
845 439-449.

846 **Ito, A., Nakao, M. and Wandra, T.** (2003b). Rapid Review: Human taeniasis and
847 cysticercosis in Asia. *Lancet* **362**, 1918-1920.

848 **Ito, A., Schantz, P. M. and Wilson, J. F.** (1995). Em18, a new serodiagnostic
849 marker for differentiation of active and inactive cases of alveolar hydatid disease.
850 *American Journal of Tropical Medicine and Hygiene* **52**, 41-44.

851 **Ito, A., Wang, X. G. and Liu, Y. H.** (1993b). Differential serodiagnosis of alveolar
852 and cystic hydatid disease in the People's Republic of China. *American Journal*
853 *of Tropical Medicine and Hygiene* **49**, 208-213.

854 **Ito, A., Ishikawa, Y., Kitada, M., Nakaya, K. and Sasajima, T.** (2003c).
855 Pulmonary alveolar echinococcosis. *Kokyu* **22**, 56-60 (in Japanese).

856 **Ito, A., Ma, L., Paul, M., Stefaniak, J. and Pawlowski, Z. S.** (1998a).
857 Evaluation of Em18-, Em16-, Antigen B-Western blots, Em2^{plus}-ELISA and four
858 other tests for differential serodiagnosis of alveolar and cystic echinococcosis
859 patients in Poland. *Parasitology International* **47**, 95-99.

860 **Ito, A., Nakao, M., Ito, Y., Yuzawa, I., Morishima, H., Kawano, N. and Fujii, K.**
861 (1999b). Neurocysticercosis case with a single cyst in the brain showing
862 dramatic drop in specific antibody titers within 1 year after curative surgical
863 resection. *Parasitology International* **48**, 95-99.

864 **Ito, A., Nakao, M., Kutsumi, H., Lightowers, M. W., Itoh, M., Sato, S.** (1993a).

865 Serodiagnosis of alveolar hydatid disease by western blotting. *Transactions of*
866 *the Royal Society of Tropical Medicine and Hygiene* **87**, 170-172,
867 **Ito, A., Li, T. Y., Chen, X. W., Long, C. P., Yanagida, T., Nakao, M., Sako, Y.,**
868 **Okamoto, M., Wu, Y., Raoul, F., Giraudoux, P. and Craig, P. S.** (2013). Mini
869 review on chemotherapy of taeniasis and cysticercosis due to *Taenia solium* in
870 Asia, and a case report with 20 tapeworms. *Tropical Biomedicine* **30**, 164-173 .
871 **Ito, A, Okamoto, M, Li, T., Wandra, T., Dharmawan, N. S., Swastika, K. I.,**
872 **Dekumyoy, P., Kusolsuk, T., Davaajav, A., Davaasuren, A., Dorjsuren, T.,**
873 **Meconnen, S. M., Negasi, Z. H., Yanagida, T., Sako, Y., Nakao, M., Nakaya,**
874 **K., Lavikainen, A. J., Nkouawa, A. and Mohammadzadeh, T.** (2011). The first
875 workshop on towards the control of cestode zoonoses in Asia and Africa.
876 *Parasites and Vectors* **4**, 114.
877 **Ito, A., Plancarte, A., Ma, L., Kong, Y., Flisser, A., Cho, Y. S., Liu, Y. H.,**
878 **Kamhawi, S., Lightowers, M. W. and Schantz, P. M.** (1998b). Novel antigens
879 for neurocysticercosis: simple method for preparation and evaluation for
880 serodiagnosis. *American Journal of Tropical Medicine and Hygiene* **59**, 291-294.
881 **Ito, A., Plancarte, A., Nakao, M., Nakaya, K., Ikejima, T., Piao, Z. X.,**
882 **Kanazawa, T. and Margono, S. S.** (1999a). ELISA and immunoblot using
883 purified glycoproteins for serodiagnosis of cysticercosis in pigs naturally infected
884 with *Taenia solium*. *Journal of Helminthology* **73**, 363-365.
885 **Ito, A., Putra, M.I., Subahar, R., Sato, M. O., Okamoto, M., Sako, Y., Nakao,**
886 **M., Yamasaki, H., Nakaya, K., Craig, P. S. and Margono, S. S.** (2002d). Dogs
887 as alternative intermediate hosts of *Taenia solium* in Papua (Irian Jaya),
888 Indonesia confirmed by highly specific ELISA and immunoblot using native and
889 recombinant antigens and mitochondrial DNA analysis. *Journal of Helminthology*
890 **76**, 311-314.
891 **Ito, A., Sako, Y., Ishikawa, Y., Nakao, M., Nakaya, K. and Yamasaki, H.**
892 (2002a). Differential serodiagnosis for alveolar echinococcosis by
893 Em18-immunoblot and Em18-ELISA in Japan and China. In *Cestode Zoonoses:*
894 *Echinococcosis and Cysticercosis – An emergent and global problem* (eds.
895 Craig, P. and Pawlowski, Z.), 147-155. IOS Press, Amsterdam.
896 **Ito, A., Sako, Y., Yamasaki, H., Mamuti, W., Nakaya, K., Nakao, M. and**

897 **Ishikawa, Y.** (2003c). Development of Em18-immunoblot and Em18-ELISA for
898 specific diagnosis of alveolar echinococcosis. *Acta Tropica* **85**, 173-182.

899 **Ito, A., Takayanagui, M. O., Sako, Y., Sato, M. O., Odashima, N. S., Yamasaki,**
900 **H., Nakaya, K. and Nakao, M.** (2006). Review: Neurocysticercosis: the
901 usefulness of highly specific serology and molecular confirmation of
902 histopathologic specimens. *Southeast Asian Journal of Tropical Medicine and*
903 *Public Health* **37** (Suppl 3), 74-81.

904 **Ito, A., Urbani, C., Qiu, J. M., Vuitton, D. A., Qiu, D. C., Heath, D. D., Craig, P.**
905 **S., Feng, Z. and Schantz, P. M.** (2003a). Control of echinococcosis and
906 cysticercosis: a public health challenge to international cooperation in China.
907 *Acta Tropica* **86**, 3-17.

908 **Ito, A., Wen, H., Craig, P. S., Ma, L., Nakao, M., Horii, T., Pang, X. L.,**
909 **Okamoto, M., Itoh, M., Osawa, Y., Wang, X. G. and Liu, Y. H.** (1997). Antibody
910 responses against Em18 and Em16 serodiagnostic markers in alveolar and
911 cystic echinococcosis patients from northwest China. *Japanese Journal of*
912 *Medical Science and Biology* **50**, 19-26.

913 **Ito, A., Xiao, N., Liance, M., Sato, M. O., Sako, Y., Mamuti, W., Ishikawa, Y.,**
914 **Nakao, M., Yamasaki, H., Nakaya, K., Bardonnnet, K., Bresson-Hadni, S. and**
915 **Vuitton, D. A.** (2002b). Evaluation of an enzyme-linked immunosorbent assay
916 (ELISA) with affinity-purified Em18 and ELISA with recombinant Em18 for
917 differential diagnosis of alveolar echinococcosis: results of a blind test. *Journal of*
918 *Clinical Microbiology* **40**, 4161-4165.

919 **Ito, A., Yamasaki, H., Nakao, M., Sako, Y., Okamoto, M., Sato, M. O., Nakaya,**
920 **K., Margono, S. S., Ikejima, T., Kassuku, A. A., Afonso, S. M. A., Benitez**
921 **Ortiz, W., Plancarte, A., Zoli, A., Geerts, S. and Craig, P. S.** (2003e). Multiple
922 genotypes of *Taenia solium*—ramifications for diagnosis, treatment and control.
923 *Acta Tropica* **87**, 95-101.

924 **Ito, A., Yanagida, T., Sako, Y., Nakao, M., Nakaya, K., Knapp, J. and Ishikawa,**
925 **Y.** (2011a). *Echinococcus* and echinococcosis. In *Molecular Detection of Human*
926 *Parasitic Pathogens* (ed. Liu, D.), 249-263. CRC Press, Boca Raton.

927 **Jiang, L., Wen, H. and Ito, A.** (2001). Immunodiagnostic differentiation of
928 alveolar and cystic echinococcosis using ELISA test with 18-kDa antigen

929 extracted from *Echinococcus* protoscoleces. *Transactions of the Royal Society*
930 *of Tropical Medicine and Hygiene* **95**, 285-288.

931 **Jiang, L., Zhang, Y. G., Liu, M. X. and Feng, Z.** (2012). Analysis of the
932 reactivity of five subunits of antigen B family in serodiagnosis of
933 echinococcosis. *Experimental Parasitology* **131**, 85-91.

934 **Jongwietiwes, U., Yanagida, T., Ito, A. and Kline, S.** (2011). Isolated
935 intradural-extramedullary spinal cysticercosis: a case report. *Journal of Travel*
936 *Medicine* **18**, 284-287.

937 **Jung-Cook, H.** (2012). Pharmacokinetic variability of anthelmintics: implications
938 for the treatment of neurocysticercosis. *Expert Review of Clinical Pharmacology*
939 **5**, 21-30.

940 **Kaji, Y., Taniyama, H., Matsukawa, K., Okada, H. Tsunoda, S., Tagami, M.**
941 **and Akita, H.** (1993). First incidence of multilocular echinococcosis in a race
942 horse in Japan. *Journal of Veterinary Medical Science* **55**, 869-870.

943 **Kawakami, H., Kuwatani, M. and Sakamoto, N.** (2013). Hepatobiliary alveolar
944 echinococcosis infiltration of the hepatic hilum diagnosed by endoscopic
945 ultrasonography-guided fine-needle aspiration. *Digestive Endoscopy* **25**,
946 339-340.

947 **Kern, P., Frosch, P., Helbig, M., Wechsler, J. G., Usadel, S., Beckh, K., Kunz,**
948 **R., Lucius, R. and Frosch, M.** (1995). Diagnosis of *Echinococcus multilocularis*
949 infection by reverse-transcription polymerase chain reaction. *Gastroenterology*
950 **109**, 596-600.

951 **Kimura, M., Toukairin, A., Tatezaki, H., Tanaka, S., Harada, K., Araiama, I.,**
952 **Yamasaki, H., Sugiyama, H., Morishima, Y. and Kawanaka, M.** (2010).
953 *Echinococcus multilocularis* detected in slaughtered pigs in Aomori the
954 northernmost prefecture of mainland Japan. *Japanese Journal of Infectious*
955 *Diseases* **63**, 80-81.

956 **Knapp, J., Chirica, M., Simonnet, C., Grenouillet, F., Bart, J. M., Sako, Y.,**
957 **Itoh, S., Nakao, M., Ito, A. and Millon, L.** (2009). *Echinococcus vogeli* infection
958 in a hunter, French Guyana. *Emerging Infectious Diseases* **15**, 2029-2031.

959 **Knapp, J., Nakao, M., Yanagida, T., Okamoto, M., Saarma, U., Lavikainen, A.**
960 **and Ito, A.** (2011). Phylogenetic relationships within *Echinococcus* and *Taenia*

961 tapeworms (Cestoda: Taeniidae): an inference from nuclear protein-coding
962 genes. *Molecular Phylogenetics and Evolution* **61**, 628-638.

963 **Kobayashi, K., Nakamura-Uchiyama, F., Nishiguchi, T., Isoda, K., Kokubo,**
964 **Y., Ando, K., Katurahara, M., Sako, Y., Yanagida, T., Ito, A., Iwabuchi, S. and**
965 **Ohnishi, K.** (2013). Rare case of disseminated cysticercosis and taeniasis in a
966 Japanese traveler after returning from India. *American Journal of Tropical*
967 *Medicine and Hygiene* **89**, 58-62.

968 **Konyaev, S., Yanagida, T., Nakao, M., Krivopalov, A., Abramov, S.,**
969 **Karpenko, S., Lopatina, N., Dupal, T., Lukmanova, G., Ingovatova, G.,**
970 **Odnokurtsev, V., Loskutova, K., Dokuchaev, N., Spiridonov, S., Tatyana, S.,**
971 **Andreyanov, O., Sako, Y. and Ito, A.** (2013). Genetic diversity of *Echinococcus*
972 spp. in Russia. *Parasitology* **140**, 1637-1647.

973 **Kumaratilake, L. M., Thompson, R. C., Eckert, J. and D'Alessandro, A.**
974 (1986). Sperm transfer in *Echinococcus* (Cestoda: Taeniidae). *Zeitschrift für*
975 *Parasitenkunde* **72**, 265-269.

976 **Lee, Y. M., Handali, S., Hancock, K., Pattabhi, S., Kovalenko, V. A., Levin, A.,**
977 **Lin, S., Scheel, C. M., Gonzalez, A. E., Gilman, R. H., Garcia, H. H. and**
978 **Tsang, V. C.** (2011). Serologic diagnosis of human *Taenia solium* cysticercosis
979 by using recombinant and synthetic antigens in QuickELISATM. *American*
980 *Journal of Tropical Medicine and Hygiene* **84**, 587-593.

981 **Li, J., Zhang, W. B., Wilson, M., Ito, A. and McManus, D. P.** (2003). A novel
982 recombinant antigen for immunodiagnosis of human cystic echinococcosis.
983 *Journal of Infectious Diseases* **188**, 1951-1960.

984 **Li, T., Chen, X., Zhen, R., Qiu, J., Qiu, D., Xiao, N., Ito, A., Wang, H.,**
985 **Giraudoux, P., Sako, Y., Nakao, M. and Craig, P. S.** (2010). Widespread
986 co-endemicity of human cystic and alveolar echinococcosis on the eastern
987 Tibetan plateau, northwest Sichuan/southeast Qinghai, China. *Acta Tropica* **113**,
988 248-256.

989 **Li, T., Ito, A., Chen, X., Sako, Y., Qiu, J., Xiao, N., Qiu, D., Nakao, M.,**
990 **Yanagida, T. and Craig, P. S.** (2010). Specific IgG responses to recombinant
991 antigen B and Em18 in cystic and alveolar echinococcosis in China. *Clinical and*
992 *Vaccine Immunology* **17**, 470-475.

993 **Liance, M., Janin, V., Bresson-Hadni, S., Vuitton, D. A., Houin, R. and**
994 **Piarroux, R.** (2000). Immunodiagnosis of *Echinococcus* infections: confirmatory
995 testing and species differentiation by a new commercial western blot. *Journal of*
996 *Clinical Microbiology* **38**, 3718-3721.

997 **Lightowers, M. W.** (2006). Cestode vaccines: origins, current status and future
998 prospects. *Parasitology* **133**, S27-S42.

999 **Lightowers, M. W.** (2010a). Fact or hypothesis: concomitant immunity in taeniid
1000 cestode infections. *Parasite Immunology* **32**, 582-589.

1001 **Lightowers, M. W.** (2010b). Fact or hypothesis: *Taenia crassiceps* as a model
1002 for *Taenia solium*, and the S3Pvac vaccine. *Parasite Immunology* **32**, 701-709.

1003 **Lightowers, M. W.** (2010c). Eradication of *Taenia solium* cysticercosis: a role
1004 for vaccination of pigs. *International Journal for Parasitology* **40**, 1183-1192.

1005 **Lightowers, M. W.** (2013). Control of *Taenia solium* taeniasis/cysticercosis:
1006 past practices and new possibilities. *Parasitology* **140**, 1566-1577.

1007 **Lymbery, A. J., Hobbs, R. P. and Thompson, R. C.** (1989). The dispersion of
1008 *Echinococcus granulosus* in the intestine of dogs. *Journal of Parasitology* **75**,
1009 562-570.

1010 **Mamunti, W., Sako, Y., Bart, J. M., Nakao, M., Ma, X., Wen, H. and Ito, A.**
1011 (2007). Molecular characterization of a novel gene encoding an 8-kDa-subunit of
1012 antigen B from *Echinococcus granulosus* genotypes 1 and 6. *Parasitology*
1013 *International* **56**, 313-316.

1014 **Mamuti, W., Yamasaki, H., Sako, Y., Nakaya, K., Nakao, M., Lightowers, M.**
1015 **W., Ito, A.** (2002). Usefulness of hydatid cyst fluid of *Echinococcus granulosus*
1016 developed in mice with secondary infection for serodiagnosis of cystic
1017 echinococcosis in humans. *Clinical Diagnostic Laboratory Immunology* **9**,
1018 573-576.

1019 **Margono, S. S., Ito, A., Sato, M. O., Okamoto, M., Subahar, R., Yamasaki, H.,**
1020 **Hamid, A., Wandra, T., Purba, W. H., Nakaya, K., Ito, M., Craig, P. S. and**
1021 **Suroso, T.** (2003). *Taenia solium* taeniasis/cysticercosis in Papua, Indonesia in
1022 2001: detection of human worm carriers. *Journal of Helminthology* **77**, 39-42.

1023 **McFadden, A. M. J., Heath, D. D., Morley, C. M. and Dorny, P.** (2011).
1024 Investigation of an outbreak of *Taenia saginata* cysts (*cysticercus bovis*) in dairy

1025 cattle from two farms. *Veterinary Parasitology* **176**, 177-184.

1026 **Mohammadzadeh, T., Sako, Y., Sadjjadi, S. M., Sarkari, B. and Ito, A.** (2012).
1027 Comparison of the usefulness of hydatid cyst fluid, native antigen B and
1028 recombinant antigen B8/1 for serological diagnosis of cystic echinococcosis.
1029 *Transactions of the Royal Society of Tropical Medicine and Hygiene* **106**,
1030 371-375.

1031 **Montresor, A. and Palmer, K.** (2006). Taeniasis/cysticercosis trend worldwide
1032 and rational for control. *Parasitology International* **55**, S301-S303.

1033 **Morel, N. Lassabe, G., Elola, S., Bondard, M., Herrera, S., Mari, C., Last, J.**
1034 **A., Jensen, O. and Gonzalez-Sapienza, G.** (2013). A monoclonal
1035 antibody-based copro-ELISA kit for canine echinococcosis to support the PAHO
1036 effort for hydatid disease control in South America. *PLoS Neglected Tropical*
1037 *Disease* **7**, e1967.

1038 **Müller, N., Frei, E., Nuñez, S. and Gottstein, B.** (2007). Improved
1039 serodiagnosis of alveolar echinococcosis of humans using an in vitro-produced
1040 *Echinococcus multilocularis* antigen. *Parasitology* **134**, 879-888.

1041 **Mwape, K. E., Phiri, I. K., Praet, N., Speyboreck, N., Muma, J. B., Dorny, P.**
1042 **and Gabriël, S.** (2013). The incidence of human cysticercosis in a rural
1043 community of eastern Zambia. *PLoS Neglected Tropical Diseases* **7**, e2142.

1044 **Nakao, M., Sako, Y. and Ito, A.** (2003). Isolation of polymorphic microsatellite
1045 loci from the tapeworm *Echinococcus multilocularis*. *Infection, Genetics and*
1046 *Evolution* **3**, 159-163.

1047 **Nakao, M., McManus, D. P., Schantz, P. M., Craig, P. S. and Ito A.** (2007). The
1048 molecular phylogeny of *Echinococcus* tapeworms based on complete
1049 mitochondrial genomic sequences. *Parasitology* **134**, 713-722.

1050 **Nako, M., Xiao, N., Okamoto, M., Yanagida, T., Sako, Y. and Ito, A.** (2009).
1051 Geographic pattern of genetic variation in the fox tapeworm *Echinococcus*
1052 *multilocularis*. *Parasitology International* **58**, 384-389.

1053 **Nakao, M., Yanagida, T., Konyaev, S., Lavikainen, A., Ondokurtsev, V.,**
1054 **Zaikov, V. and Ito, A.** (2013a). Mitochondrial phylogeny of the genus
1055 *Echinococcus* (Cestoda: Taeniidae) with emphasis on relationships among
1056 *Echinococcus canadensis* genotypes. *Parasitology* **140**, 1625-1636.

1057 **Nakao, M., Yanagida, T., Okamoto, M., Knapp, J., Nkouawa, A., Sako, Y. and**
1058 **Ito, A.** (2010). State-of-the-Art *Echinococcus* and *Taenia*: phylogenetic
1059 taxonomy and its application to molecular diagnosis. *Infection, Genetics and*
1060 *Evolution* **10**, 444-452.

1061 **Nakao, M., Lavikainen, A., Iwaki, T., Haukisalmi, V., Konyaev, S., Oku, Y.,**
1062 **Okamoto, M. and Ito, A.** (2013b). Molecular phylogeny of the genus *Taenia*
1063 (Cestoda: Taeniidae): Proposals for the resurrection of *Hydatigera* Lamarck,
1064 1816 and the creation of a new genus *Versteria*. *International Journal for*
1065 *Parasitology* **43**, 427-437.

1066 **Nash, T. E. and Garcia, H. H.** (2011). Diagnosis and treatment of
1067 neurocysticercosis. *Nature reviews. Neurology* **7**, 584-594.

1068 **Nirmalan, N. and Craig, P.S.** (1997). Immunoblot evaluation of the
1069 species-specificity of Em18 and Em16 antigens for serodiagnosis of human
1070 alveolar echinococcosis. *Transactions of the Royal Society of Tropical Medicine*
1071 *and Hygiene* **91**, 484-486.

1072 **Nkouawa, A., Sako, Y., Nakao, M., Nakaya, K. and Ito, A.** (2009).
1073 Loop-mediated isothermal amplification method for differentiation and rapid
1074 detection of *Taenia* species. *Journal of Clinical Microbiology* **47**, 168-174.

1075 **Nkouawa, A., Sako, Y., Li, T., Chen, X., Wandra, T., Swastika, K., Nakao, M.,**
1076 **Yanagida, T., Nakaya, K., Qiu, D. and Ito, A.** (2010). Evaluation of
1077 loop-mediated isothermal amplification method using fecal specimens for
1078 differential detection of *Taenia* species. *Journal of Clinical Microbiology* **48**,
1079 3350-3352.

1080 **Nkouawa, A., Sako, Y., Itoh, S., Koujip-Mabou, A., Nganou, C.N., Saijo, Y.,**
1081 **Knapp, J., Yamasaki, H., Nakao, M., Nakaya, K., Moyou-Somo, R. and Ito, A.**
1082 (2011). Serological studies of neurologic helminthic infections in rural areas of
1083 southwest Cameroon: toxocariasis, cysticercosis and paragonimiasis. *PLoS*
1084 *Neglected Tropical Diseases* **6**, e732.

1085 **Nkouawa, A., Sako, Y., Li, T., Chen, X., Nakao, M., Yanagida, T., Okamoto, M.,**
1086 **Giraudoux, P., Raoul, F., Nakaya, K., Xiao, N., Qiu, J., Qiu, D., Craig, P. S.**
1087 **and Ito, A.** (2012). Loop-mediated isothermal amplification method for a
1088 differential identification of *Taenia* tapeworms from human: application to a field

1089 survey. *Parasitology International* **61**, 723-725.

1090 **Nonaka, N., Iida, M., Yagi, K., Ito, T., Ooi, H. K., Oku, Y. and Kamiya, M.**
1091 (1996). Time course of coproantigen excretion in *Echinococcus multilocularis*
1092 infections in foxes and an alternative definitive host, golden hamsters.
1093 *International Journal for Parasitology* **26**, 1271-1278.

1094 **Obal, G., Ramos, A. L., Silva, V., Lima, A., Battyany, C., Bessio, M. I.,**
1095 **Ferreira, F., Salinas, G. and Ferreira, A. M.** (2012). Characterisation of the
1096 native lipid moiety of *Echinococcus granulosus* antigen B. *PLoS Neglected*
1097 *Tropical Diseases* **6**, e1642.

1098 **Okamoto, M., Nakao, M., Blair, D., Anantaphruti, M. T., Waikagul, J. and Ito,**
1099 **A.** (2010). Evidence of hybridization between *Taenia saginata* and *Taenia*
1100 *asiatica*. *Parasitology International* **59**, 70-74.

1101 **Pawlowski, Z. S.** (2006). Role of chemotherapy of taeniasis in prevention of
1102 neurocysticercosis. *Parasitology International* **55**, S105-S109.

1103 **Raoul, F., Deplazes, P., Nonaka, N., Piarroux, R., Vuitton, D. A. and**
1104 **Giraudoux, P.** (2001). Assessment of the epidemiological status of
1105 *Echinococcus multilocularis* in foxes in France using ELISA coprotests on fox
1106 faeces collected in the field. *International Journal for Parasitology* **31**,
1107 1579-1588.

1108 **Sako, Y., Itoh, S., Okamoto, M., Nakaya, K. and Ito, A.** (2013). Simple and
1109 reliable preparation of immunodiagnostic antigens from *Taenia solium* cyst fluids.
1110 *Parasitology* **140**, 1589-1594.

1111 **Sako, Y., Nakao, M., Ikejima, T., Piao, X. Z., Nakaya, K. and Ito, A.** (2000).
1112 Molecular characterization and diagnostic value of *Taenia solium*
1113 low-molecular-weight antigen genes. *Journal of Clinical Microbiology* **38**,
1114 4439-4444.

1115 **Sako, Y., Nakao, M., Nakaya, K., Yamasaki, H., Gottstein, B., Lightowlers, M.**
1116 **W., Schantz, P. M. and Ito, A.** (2002). Alveolar echinococcosis: characterization
1117 of diagnostic antigen Em18 and serological evaluation of recombinant Em18.
1118 *Journal of Clinical Microbiology* **40**, 2760-2765.

1119 **Sako, Y., Tappe, D., Fukuda, K., Kobayashi, Y., Itoh, S., Frosch, M., Grüner,**
1120 **B., Kern, P. and Ito, A.** (2011). An immunochromatographic test with

1121 recombinant Em18 antigen for the follow-up study of alveolar echinococcosis.
1122 *Clinical and Vaccine Immunology* **18**, 1302-1305.

1123 **Salim, L., Ang, A., Handali, S., Cysticercosis Working Group in Papua and**
1124 **Tsang, V. C.** (2009). Seroepidemiologic survey of cysticercosis-taeniasis in four
1125 central highland districts of Papua, Indonesia. *American Journal of Tropical*
1126 *Medicine and Hygiene* **80**, 384-388.

1127 **Santivañez, S. J., Arias, P., Portocarrero, M., Rodriguez, S., Gonzalez, A. E.,**
1128 **Gilman, R. H., Gavidia, C. M. and Garcia, H. H.** (2012). Serological diagnosis
1129 of lung cystic hydatid disease using the synthetic p176 peptide. *Clinical and*
1130 *Vaccine Immunology* **19**, 944-947.

1131 **Santos, G. B., Soares, M. de C. P., Brito, E. M. de F., Rodrigues, A. L.,**
1132 **Siqueira, N. G., Gomes-Gouvêa, M. S., Alves, M. M., Carneiro, L. A.,**
1133 **Malheiros, A. P., Póvoa, M. M., Zaha, A. and Haag, K. L.** (2012).
1134 Mitochondrial and nuclear sequence polymorphisms reveal geographic
1135 structuring in Amazonian populations of *Echinococcus vogeli* (Cestoda:
1136 Taeniidae). *International Journal for Parasitology* **42**, 1115-1118.

1137 **Sato, M. O., Yamasaki, H., Sako, Y., Nakao, M., Nakaya, K., Plancarte, A.,**
1138 **Kassuku, A. A., Dorny, P., Geerts, S., Benitz-Orgiz, W., Hashiguchi, Y. and**
1139 **Ito, A.** (2003). Evaluation of tongue inspection and serology for diagnosis of
1140 *Taenia solium* cysticercosis in swine: usefulness of ELISA using purified
1141 glycoproteins and recombinant antigen. *Veterinary Parasitology* **111**, 309-322.

1142 **Schantz, P. M.,** (2006). Progress in diagnosis, treatment and elimination of
1143 echinococcosis and cysticercosis. *Parasitology International* **55**, S7-S13.

1144 **Schantz, P. M., Cruz, M., Sarti, E. and Pawlowski, Z.** (1993). Potential
1145 eradicability of taeniasis and cysticercosis. *Bulletin of the Pan American Health*
1146 *Organization* **27**, 397-403.

1147 **Serpa, J. A., Graviss, E. A., Kass, J. S. and White, A. C. Jr.** (2011).
1148 Neurocysticercosis in Houston, Texas: an update. *Medicine (Baltimore)* **90**,
1149 81-86.

1150 **Siles-Lucas, M. M. and Gottstein, B.** (2001). Molecular tools for the diagnosis
1151 of cystic and alveolar echinococcosis. *Tropical Medicine and International Health*
1152 **6**, 463-475.

1153 **Simanjuntak, G. M., Margono, S. S., Okamoto, M. and Ito, A.** (1997).
1154 Taeniasis/cysticercosis in Indonesia as an emerging disease. *Parasitology*
1155 *Today* **13**, 321-323.

1156 **Snabel, V., Altintas, N., D'Amelio, S., Nakao, M., Romig, T., Yolasigmaz, A.,**
1157 **Gunes, K., Turk, M., Busi, M., Huttner, D., Sevcova, D., Ito, A., Altintas, N.**
1158 **and Dubinsky, P.** (2009). Cystic echinococcosis in Turkey: genetic variability
1159 and first record of the pig strain (G7) in the country. *Parasitology Research* **105**,
1160 145-154.

1161 **Sorvillo, F., Wilkins, P., Shafir, S. and Ebenbard, M.** (2011). Public health
1162 implications of cysticercosis acquired in the United States. *Emerging Infectious*
1163 *Diseases* **17**, 1-6.

1164 **Subahar, R., Hamid, A., Purba, W., Wandra, T., Karma, C., Sako, Y., Margono,**
1165 **S. S., Craig, P. S. and Ito, A.** (2001). *Taeniasis solium* infection in Irian Jaya
1166 (West Papua), Indonesia: a pilot serological survey of human and porcine
1167 cysticercosis in Jayawijaya District. *Transactions of the Royal Society of Tropical*
1168 *Medicine and Hygiene* **95**, 388-390.

1169 **Swastika, K. Dewiyani, C. I., Yanagida, T., Sako, Y., Sudamaja, M., Sutisna,**
1170 **P., Wandra, T., Dharmawan, N. S., Nakaya, K., Okamoto, M. and Ito, A.** (2012).
1171 An ocular cysticercosis in Bali, Indonesia caused by *Taenia solium* Asian
1172 genotype. *Parasitology International* **61**, 378-380.

1173 **Takayanagui, O. M., Odashima, N. S., Bonato, P. S., Lima, J. E. and**
1174 **Lanchote, V. L.** (2011). Medical management of neurocysticercosis. *Expert*
1175 *Opinion on Pharmacotherapy* **12**, 2845-2856.

1176 **Tappe, D., Grüner, B., Kern, P. and Frosch, M.** (2008). Evaluation of a
1177 commercial *Echinococcus* western blot assay for serological follow-up of
1178 patients with alveolar echinococcosis. *Clinical and Vaccine Immunology* **15**,
1179 1633-1637.

1180 **Tappe, D., Grüner, B., Kern, P. and Frosch, M.** (2009). Banding pattern
1181 indicative of echinococcosis in a commercial cysticercosis western blot.
1182 *European Journal of Medical Research* **14**, 451-452.

1183 **Tappe, D., Sako, Y., Itoh, S., Frosch, M., Grüner, B., Kern, P. and Ito, A.**
1184 (2010). Immunoglobulin G subclass responses to recombinant Em18 in the

1185 follow-up of patients with alveolar echinococcosis in different clinical stages.
1186 *Clinical and Vaccine Immunology* **17**, 944-948.

1187 **Tappe, D., Sako, Y., Itoh, S., Frosch, M., Grüner, B., Reuter, S., Nakao, M., Ito,**
1188 **A. and Kern, P.** (2009). Close correlation of clinical regression and specific
1189 serology in the follow-up of patients with alveolar echinococcosis in different
1190 clinical stages. *American Journal of Tropical Medicine and Hygiene* **80**, 792-797.

1191 **Thompson, R. C. and Eckert, J.** (1983). Observation on *Echinococcus*
1192 *multilocularis* in the definitive host. *Zeitschrift für Parasitenkunde* **69**, 335-345.

1193 **Ueno, M., Kuroda, N., Yahagi, K., Ohtaki, T. and Kawanaka, M.** (2012).
1194 Analysis of antibody responses by commercial western blot assay in horses
1195 infected with alveolar echinococcosis. *Journal of Veterinary Medicine and*
1196 *Science* **74**, 813-815.

1197 **Wandra, T., Ito, A. Swastika, K., Dharmawan, N. S., Sako, Y. and Okamoto,**
1198 **M.** (2013). The past and present situation of taeniasis and cysticercosis in
1199 Indonesia. *Parasitology* **140**, 1608-1616.

1200 **Wandra, T., Sudewi, R. A. A., Swastika, I. K., Sutisna, P., Dharmawan, N. S.,**
1201 **Yulfi, H., Darlan, D. M., Kapti, I. N., Samaan, G., Sato, M. O., Okamoto, M.,**
1202 **Sako, Y. and Ito, A.** (2011). Taeniasis/cysticercosis in Bali, Indonesia. *Southeast*
1203 *Asian Journal of Tropical Medicine and Public Health* **42**, 793-802.

1204 **Wandra, T., Subahar, R., Simanjuntak, G. M., Margono, S. S., Suroso, T.,**
1205 **Okamoto, M., Nakao, M., Sako, Y., Nakaya, K., Schantz, P. M. and Ito, A.**
1206 (2000). Resurgence of cases of epileptic seizures and burns associated with
1207 cysticercosis in Assologaima, Jayawijaya, Irian Jaya, Indonesia, 1991-95.
1208 *Transactions of the Royal Society of Tropical Medicine and Hygiene* **94**, 46-50.

1209 **Wen, H. and Craig, P. S.** (1994). Immunoglobulin G subclass responses in
1210 human cystic and alveolar echinococcosis. *American Journal of Tropical*
1211 *Medicine and Hygiene* **51**, 741-748.

1212 **Xiao, N., Mamuti, W., Yamasaki, H., Sako, Y., Nakao, M., Nakaya, K.,**
1213 **Gottstein, B., Schantz, P. M., Lightowers, M. W., Craig, P. S. and Ito, A.**
1214 (2003). Evaluation of use of recombinant Em18 and affinity-purified Em18 for
1215 serological differentiation of alveolar echinococcosis from cystic echinococcosis
1216 and other parasitic infections. *Journal of Clinical Microbiology* **41**, 3351-3353.

1217 **Xiao, N., Qiu, J., Nakao, M., Li, T., Yang, W., Chen, X., Schantz, P. M., Craig, P.**
1218 **S. and Ito, A.** (2005). *Echinococcus shiquicus* n. sp., a taeniid cestode from
1219 Tibetan foxes and plateau pikas in China. *International Journal for Parasitology*
1220 **35**, 693-701.

1221 **Yamamoto, N., Morishima, Y., Kon, M., Yamaguchi, M., Tanno, S., Koyama,**
1222 **M., Maeno, N. Azuma, H., Mizusawa, H., Kimura, H., Sugiyama, H., Arakawa,**
1223 **K. and Kawanaka, M.** (2006). The first reported case of a dog infected with
1224 *Echinococcus multilocularis* in Saitama prefecture, Japan. *Japanese Journal of*
1225 *Infectious Diseases* **59**, 351-352.

1226 **Yamane, K., Suzuki, Y., Tachi, E., Li, T. Y., Chen, X. W., Nakao, M., Nkouawa,**
1227 **A., Yanagida, T., Sako, Y., Ito, A., Sato, H. and Okamoto, M.** (2012). Recent
1228 hybridization between *Taenia asiatica* and *Taenia saginata*. *Parasitology*
1229 *International* **61**, 351-355.

1230 **Yamane, K., Yanagida, T., Li, T., Chen, X., Dekumyoy, P., Waikagul, J.,**
1231 **Nkouawa, A., Nakao, M., Sako, Y., Ito, A., Sato, H. and Okamoto, M.** (2013).
1232 Complicated relationships between *Taenia saginata*, *Taenia asiatica* and their
1233 hybrids. *Parasitology* **140**, 1595-1601.

1234 **Yamano, K., Yagi, K., Furuya, K., Sawada, Y., Honma, H and Sato, N.** (2005).
1235 Active alveolar hydatidosis with sero-negativity for antibody to the 18kDa antigen.
1236 *Japanese Journal of Infectious Diseases* **58**, 122-124.

1237 **Yamasaki, H.** (2013). Current status and perspectives of cysticercosis and
1238 taeniasis in Japan. *Korean Journal of Parasitology* **51**, 19-29.

1239 **Yamasaki, H., Allan, J. C., Sato, M. O., Nakao, M., Sako, Y., Nakaya, K., Qiu,**
1240 **D. C., Mamuti, W., Craig, P. S. and Ito, A.** (2004). DNA differential diagnosis of
1241 taeniasis/cysticercosis by multiplex PCR. *Journal of Clinical Microbiology* **42**,
1242 548-553.

1243 **Yanagida, T., Yuzawa, I., Joshi, D. D., Sako, Y., Nakao, M., Nakaya, K.,**
1244 **Kawano, N., Oka, H., Fujii, K. and Ito, A.** (2010). Neurocysticercosis:
1245 assessing where the infection was acquired? *Journal of Travel Medicine* **17**,
1246 206-208.

1247 **Yanagida, T., Sako, Y., Nakao, M., Nakaya, K. and Ito, A.** (2012). Mini Review:
1248 Taeniasis and cysticercosis due to *Taenia solium* in Japan. *Parasites and*

1249 *Vectors* **5**, 18.

1250 **Yang, Y. R., Craig, P. S., Ito, A., Vuitton, D. A., Giraudoux, P., Sun, T.,**
1251 **Williams, G. M., Huang, Z., Li, Z., Wang, Y., Teng, J., Li, Y., Huang, L., Wen,**
1252 **H., Jones, M. K. and McManus, D. P. (2007).** A correlative studies of ultrasound
1253 with serology in an area in China co-endemic for human alveolar and cystic
1254 echinococcosis. *Tropical Medicine and International Health* **12**, 637-646.


1255 **Yu, S. H., Wang, H., Wu, X. H., Ma, X., Liu, P. Y., Liu, Y. F., Zhao, Y. M.,**
1256 **Morishima, Y. and Kawanaka, M. (2008).** *Japanese Journal of Infectious*
1257 *Diseases* **61**, 242-246.

1258

1259

1260 Figure legends

1261




1262

1263

1264 Fig. 1. Schematic figure of AE, CE and non-echinococcal cases including cysticercosis
1265 (CC) detectable by western blots (WB) using RecEm18, RecAgB (Ito *et al.* 1993b, 1995,
1266 1997, 1998a) and commercially available crude antigen-WB P1-P5 (Liance *et al.* 2000).
1267 The majority of AE and CE cases except some early or abortive stage of AE and CE are
1268 easily detected by RecEm18 and RecAgB, respectively (Li *et al.* 2010) and by WB:P3
1269 (WB:P3 (+) in Fig. 1) for detection of mainly Em18 (Ito *et al.* 1993b, 1995, 1997,
1270 1998a) and WB:P1, P2 (WB:P1, P2 (+) in Fig. 1) for detection of mainly AgB (8 kDa),
1271 respectively (Ito *et al.* 1997, 1998a; Liance *et al.* 2000). WB:P4, P5 (P4, P5 (+) in Fig.
1272 1) may include echinococcosis, either CE or AE but they are positive under blind test
1273 for CC and some other diseases and no use under a blind test or screening (Liance *et al.*
1274 2000). The real confirmative WB for AE and CE are based on detection of AgB, Em16,

1275 Em18 at least and P1, P2, P3 but not P4, P5 (Liance *et al.* 2000). Based on the banding
 1276 patterns using crude antigens, we can identify AE by detection of antibody responses to
 1277 Em18 or both Em18 and Em16, and CE by those responses to Em16 and AgB (Ito *et al.*
 1278 1993, 1995, 1997, 2002a, b; Furuya *et al.* 2004; Tappe *et al.* 2008). However, we cannot
 1279 identify AE and CE by crude antigen-ELISA, since crude antigens have many
 1280 non-specific components shared between the host and parasite. More important is that
 1281 these serological tools cannot always detect early stages of AE or CE.
 1282
 1283



1284
 1285
 1286 Fig. 2. The rapid declines in antibody responses in two resected hepatic AE cases (PNM
 1287 stage I) (a and c: modified from Akabane *et al.* 2012; b and d: modified from Akabane
 1288 *et al.* in prep.). ELISA (a and b) and WB (c and d) using RecEm18 (Sako *et al.* 2002)
 1289 before surgery until 60 months (a and c) and until 17 months after surgery (b and d).
 1290
 1291



1292

1293

1294 Fig. 3. A one year old pig full of cysticerci of *T. solium* in Bali, Indonesia, suspected to
1295 be infected based on ELISA in the field and judged by our naked eyes in Jan 2013. Such
1296 a pig is sufficient for local personnel to prepare huge amount of diagnostic antigens.